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ABSTRACT 
 
Charles Micha Belden I: Organizational Determinants of Minority Participation in Clinical 
Research 
(Under the direction of Bryan Weiner) 
 
Poor rates of minority participation in cancer clinical trials, and inequitable distribution 
of results from clinical research contribute to persistent disparities in cancer care outcomes. 
Systematic reviews of minority participation in clinical trials reveal extensive research on patient 
and provider-level barriers to participation; however, there is limited research on the 
organizational drivers of minority enrollment in treatment trials. The goal of this dissertation is 
to enhance our understanding of the organizational determinants of minority participation in 
cancer treatment trials. The objectives of this dissertation are: (1) estimate the impact of 
organizational characteristics associated with black enrollment in National Cancer Institute 
(NCI) sponsored treatment trials offered by organizations participating in the NCI Community 
Clinical Oncology Program; (2) examine the strategies of organizations participating in the NCI 
Community Clinical Oncology Program resulting in high enrollment of minorities in National 
Cancer Institute (NCI) sponsored treatment trials; and (3) evaluate disparities in geographic 
access to organizations offering National Cancer Institute (NCI) sponsored treatment trials for 
minority populations in the continental United States. 
The first study employs a multivariate regression approach to estimate the impact of 
organizational characteristics on enrollment of blacks in treatment trials. The second study 
employed a fuzzy-set qualitative comparative analysis to investigate organizational strategies, 
 iv 
comprised of tactics, which achieve high enrollment of minorities in treatment trials as defined 
by NCI officials. Finally, a network analysis approach was employed using ZIP code tabulation 
area (ZCTA) data, and geocoded locations of organizations offering NCI-sponsored trials in 
order to investigate disparities in geographic access to CTOs. 
Results from the three studies have theoretical, practical, and policy implications. This 
dissertation provides empirical support for Ford and colleagues conceptual framework describing 
barriers and facilitators to underrepresented populations’ participation in clinical trials. CTO 
leaders can use findings from this dissertation to enhance their strategies to enroll minority 
patients in clinical treatment trials. Additionally, whereas our results demonstrate that overall 
geographic access to CTOs is excellent, policymakers can use the findings from the network 
analysis in order to address disparities in geographic access to CTOs for racial and ethnic groups 
residing far from CTOs. 
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CHAPTER 1: INTRODUCTION 
 
Clinical treatment trials are considered the gold standard for evaluating the efficacy of 
cancer therapeutic regimens. Racial and ethnic diversity among clinical trial participants is 
critical in order to evaluate therapeutic effects, and ensure that the burdens and benefits of cancer 
clinical research are equitably shared. However, disparities in minority participation in clinical 
trials have been long-standing and well documented in the US. Estimates suggest that 3-5% of 
adult cancer patients in the US participate in a clinical trial, but less than less than 3% of 
minority cancer patients participate in trials despite extensive Federal efforts to promote the 
development of organizations intended to enhance minority participation in clinical research 
(NCI Cancer Bulletin, 2010). Moreover, studies have demonstrated an overall decline in 
minority participation in clinical research in recent years (Murthy, et. al., 2004), which may 
exacerbate disparities in the receipt of high-quality cancer care (Carpenter, et. al., 2011; Laliberte, 
et. al., 2005; Johnson, et. al., 1994). In order to improve minority participation in clinical 
research, and specifically treatment trials, it is essential that we improve our understanding of the 
organizational determinants of minority participation in clinical treatment trials. 
Cancer care organizations provide a wide variety of treatment and prevention services to 
patients in the United States (US). The majority of cancer patients in the US seek care in 
community-based cancer care organizations; and for over 30 years, the National Institutes of 
Health (NIH) has promoted cancer care organizations that enhance overall and minority 
participation in clinical trials by funding collaborations between academically based researchers 
and community-based physicians. In 1983, the National Cancer Institute (NCI) initiated the 
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Community Clinical Oncology Program to foster the development of a provider-based research 
network (PBRN), comprised of community-based clinical trial organizations (CTOs) located 
throughout the US. The specific goals of this NIH endeavor have focused on promoting the 
implementation of CTOs that: (a) advance scientific discoveries in cancer therapies through 
conducting clinical trials in community-based locations; and (b) accelerate the translation and 
dissemination of clinical trial results into community-based practice settings. In addition to 
CTOs funded by the NCI Community Clinical Oncology Program, the American College of 
Surgeons Commission on Cancer (ACS-COC) has a long history of efforts aimed at improving 
cancer care, and specifically accredit cancer care organizations that offer clinical trials to patients 
in both academic and community-based hospital settings. Cancer care organizations accredited 
by ACS-COC that offer clinical trials to patients are included in the analysis presented in 
Chapter 4 as CTOs. 
CTOs are organizations of specialists, primary care physicians, and other staff linked to 
NCI Cancer Centers and Research bases where treatment trials are initiated. Indeed, recent 
research has shown that CTOs have demonstrated their ability to address disparities in cancer 
care at the local level (Wheeler, et. al., 2012; Vicini, 2011).  A physician principal investigator 
provides overall leadership for the CTOs’ physicians and staff members; and CTO staffs vary in 
their composition, and may include program coordinators, research nurses, clinical research 
associates, data managers, and regulatory specialists. Staff members coordinate the review and 
selection of clinical treatment trial, disseminate protocols to participating physicians, and other 
staff members; and collect and submit study data. CTO physicians refer or enroll patients to 
clinical trials, and typically include cadres comprise of medical, surgical and radiation 
oncologists, general surgeons, urologists, gastroenterologists, and primary care physicians. 
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Through their collaboration with NCI research bases, CTO affiliated physicians may also 
participate in the development of clinical trials by proposing potential study ideas, providing 
input on study designs, and serving as a principal investigator or co-principal investigator for 
trials (Macaulay & Nutting, et. al., 2006). However, CTOs are challenging to implement and 
sustain. Challenges include obtaining sustainable funding, creating the infrastructure for clinical 
trial enrollment, locating and opening appropriate clinical trials appropriate for the populations 
served, managing complex regulatory compliance issues, and sustaining ongoing participation 
from community-based physicians.  
Patient and physician level factors associated with minority participation in clinical 
research have been studied exhaustively, and included in several recent literature reviews (Rivers, 
et. al., 2014; Schmotzer, 2012; Ford, et. al., 2008), however, limited research has investigated the 
organizational characteristics associated with minority enrollment in clinical treatment trials (Lai, 
et al., 2006). Studies have sought to identify organizational characteristics associated with 
overall enrollment of patients to clinical trials at CTOs (Carpenter, et. al., 2012; Weiner, et. al., 
2012; Jacobs, et. al., 2013), but these studies did not examine minority enrollment. This gap in 
research limits the ability to effectively develop policies and strategies to address disparities in 
minority participation in clinical research, and thus, it is critical for further studies to examine the 
impact of organizational factors associated with minority enrollment in clinical trials. This 
dissertation seeks to enhance our understanding of the role of organizational characteristics 
associated with the enrollment of minority populations in NCI-sponsored. The specific research 
objectives are: (1) examine the organizational characteristics associated with African American 
participation in NCI-sponsored clinical treatment trials; (2) examine the organizational strategies 
of CTOs resulting in high enrollment of minority patients in NCI-sponsored clinical treatment 
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trials; and (3) examine disparities in geographic access to cancer care organizations offering 
NCI-sponsored clinical trials (CTOs) in the continental United States. The central hypothesis is 
that organizational factors directly impact the enrollment of minorities in clinical research. This 
central hypothesis is tested with three research aims: 
 Aim 1: Estimate the impact of organizational characteristics on African American 
enrollment in NCI-sponsored clinical treatment trials available through PBRNs 
participating in the Community Clinical Oncology Program.  
 Aim 2: Identify organizational strategies associated with high enrollment of 
minorities in NCI-sponsored clinical treatment trials among PBRNs participating in 
the Community Clinical Oncology Program.  
 Aim 3: Examine disparities in geographic access to CTOs for demographic groups 
in the continental US.  
Data for this dissertation were drawn from 7 sources: 1) 2010-2012 NCI Annual 
Community Clinical Oncology Program Progress Reports; 2) 2011 Community Clinical 
Oncology Program Administrator Survey; 3) 2010-2012 American Community Surveys; 4) 
Kaiser Family Foundation; 5) National Cancer Institute website; 6) American College of 
Surgeons Commission (ACSO) on Cancer database; and the 7) Association of American Medical 
Colleges, Council of Teaching Hospitals database.  
Annual counts of black patients enrolled in clinical treatment trials by CTOs participating 
in the Community Clinical Oncology program were drawn from the NCI Annual Progress 
Reports and used as the dependent variable for Aim 1. Annual counts of minority patients 
enrolled in trials drawn from the reports are the outcome of interest for Aim 2. Names and 
locations for each of the CTO’s enrolling sites were also drawn from the Annual Progress 
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Reports and used in the development of the geographic information system (GIS) for Aims 1 and 
3. A survey of CTOs delivered to program administrators, and conducted from 2011-2012, 
collected detailed organizational characteristics of the CTOs participating in the Community 
Clinical Oncology Program for Aims 1 and 2. American Community Surveys (ACS) provided 
data on metropolitan statistical area (MSA) demographic characteristics for black populations in 
the US for the multivariate regression analysis in Aim 1. Additional data for Aim 1 on CTO 
environmental context were drawn from the Kaiser Family Foundation website. In addition to the 
locations of enrolling sites of the Community Clinical Oncology Program for the GIS employed 
in Aims 1 and 3, the National Cancer Institute’s website provided names and addresses for NCI-
designated Comprehensive Cancer Centers in the US; the American College of Surgeons 
database provided names and addresses for accredited Commission on Cancer hospitals enrolling 
patients in clinical trials; and the Council of Teaching Hospitals provided names and addresses 
for academic medical centers.  
 This dissertation employs three distinct analytical approaches in order to examine 
organizational determinants of minority participation in NCI-funded clinical treatment trials. 
Aim 1 in this dissertation employs a multivariate regression approach in order to examine the 
impact of organizational factors on the enrollment of black Americans in clinical treatment trials. 
Aim 2 employs a fuzzy-set qualitative comparative analysis in order to identify the 
organizational strategies resulting in high organizational enrollment of minorities to clinical 
treatment trials. And Aim 3 employs a network geographic analysis in order to estimate median 
travel times from zip code tabulation area (ZCTA) centroids to he nearest CTO for racial and 
ethnic groups in the continental US. The geographic information system (GIS) capturing the 
locations of CTOs in the US underlies the overall study aims; specifically provides a measure of 
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hospital competition for Aim 1, and was employed as the analytical tool used to investigate 
disparities in geographic access to clinical trial organizations with estimated travel times for 
populations in the continental US in Aim 3.  
The multivariate regression approach of Aim 1 presented in Chapter 2 focuses on the 
impact of organizational-level characteristics on black enrollment in clinical treatment trials. 
Aim 1 follows on Carpenter and colleagues’ studies of organizational and market characteristics 
associated with overall enrollment in treatment trials by CTOs participating in the Community 
Clinical Oncology Program (2012, 2006). Organizational-level characteristics associated with 
black enrollment are examined since previous studies have extensively studied patient and 
provider-level data, and did not employ probabilistic analytical approaches. Moreover, detailed 
information on race or ethnicity, geographic location, and other socioeconomic characteristics of 
patients enrolled in clinical trials by specific physicians participating in the Community Clinical 
Oncology program is not available. Disparities in minority enrollment in clinical trials is the 
overall issue addressed in this dissertation; however, there is wide variation in the educational 
attainment, insurance coverage, and unemployment by racial and ethnic minority groups, and by 
region; thus Black enrollment was selected as the dependent variable of interest in Aim 1 
because it specifically allows for the control of potentially endogenous socioeconomic factors 
(education, insurance, unemployment) using metropolitan statistical area data linked to each 
CTO. The multivariate regression approach employed in Aim 1 was also selected in order to 
estimate the net impact (marginal effects) of organizational characteristics on black enrollment in 
cancer clinical treatment trials. Examining the net impact of organizational characteristics on 
black enrollment allows us to understand which organizational factors are associated with 
enrollment, and the effect they have on enrollment while simultaneously controlling for the 
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effects of other organizational characteristics and potentially endogenous market-level factors 
(Carpenter, et. al., 2006).  
The contribution of Aim 1 is significant because it will improve our understanding of the 
organizational factors that influence black participation in clinical treatment trials, and therefore 
enhance efforts to increase black participation. Previous research examining the impact of 
organizational characteristics of CTOs on overall treatment trial enrollment found that the 
number of trials available and trial-enrolling physicians were significantly associated with 
enrollment of patients in clinical treatment trials; and whereas greater hospital competition 
resulted in lower enrollment, results indicated that managed care penetration was positively 
associated with enrollment during early stages, and declined in later stages (Carpenter, et. al., 
2006). A more recent study by Carpenter and colleagues (2012) reexamining the CTOs found 
that organizational characteristics remained significant; however, the only significant market-
level factor was the proportion of nearby hospitals with medical school affiliations. 
Unfortunately, these studies did not examine black participation in clinical treatment trials, and it 
is unknown whether organizational characteristics have the same impact on black enrollment. 
For example, whereas a greater number of enrolling physicians are positively associated with 
overall clinical treatment trial enrollment; it is possible that a few physicians located in a densely 
populated minority region can enroll substantial numbers of black or minority patients in trials. 
Aim 1 is particularly relevant to the current reorganization of NCI’s clinical trials infrastructure, 
and its mandate to continue addressing disparities in cancer care. A specific policy concern 
addressed in Aim 1 is the continued funding of CTOs that serve large minority populations. 
Whereas the NCI has funded community-based organizations focused on enrolling minority 
populations in clinical research since 1990, more evidence is needed to ensure that funding 
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minority-based organizations is an effective approach to enhancing minority participation in 
clinical research. Many of the CTOs examined in this study that serve large minority populations 
fail to enroll the minimum number of patients per NCI guidelines; however, they typically have 
fewer resources than CTOs that do not serve large minority populations. Aim 1 demonstrates that 
holding other organizational characteristics constant, CTOs serving large minority populations 
enroll significantly more blacks to clinical treatment trials. Additionally, in order to address the 
substantial number of barriers that black participants face (George, et. al., 2014; Rivers, et. al., 
2013), a larger research staff may be necessary to enroll black patients in clinical treatment 
trials (Ghebre, et. al., 2014; Green, et. al., 2013). 
The fuzzy-set qualitative comparative analysis (fsQCA) approach presented in Chapter 3 
focuses on organizational strategies resulting in high enrollment of minorities in treatment trials. 
In this analysis, an organizational strategy consists of multiple tactics, and different combinations 
of tactics may result in high enrollment of minorities in treatment trials. Aim 2 seeks to improve 
our understanding of both the individual organizational design features, and combinations of 
individual design features that result in high enrollment of minorities in clinical treatment trials. 
The outcome of interest in Aim 2, minority enrollment in treatment trials, differs from Aim 1 due 
to the strength of the fsQCA case study approach to examine the organizational design features 
of PBRNs that achieve high minority enrollment without concerns for missing endogenous 
individual or contextual socioeconomic determinants of enrollment. The fsQCA case study 
approach differs from the probabilistic approach from Aim 1, and specifically utilizes Boolean 
logic to investigate the individual organizational design features that are necessary for high 
enrollment of minorities; and combinations of design features that are sufficient for achieving 
high minority enrollment.  
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The contribution of Aim 2 is significant because it provides a limited number of 
evidence-based organizational strategies that result in high enrollment of minorities in clinical 
treatment trials that may be employed to enhance overall minority participation in clinical 
research. Previous research on Community Clinical Oncology Program CTOs suggest that 
enrollment of patients in clinical trials varies with certain organizational factors (Teal, et. al. 
2012; Clauser, et. al., 2009; McKinney, et. al., 2006; Weiner, et. al., 2006; Kaluzny, et. al., 1989). 
For example, studies examining specific organizational design features resulting in minority 
enrollment have suggested community-based participatory research approaches, outreach and 
trainings (Vicini, et. al., 2011), or patient navigation programs (Holmes DR, et. al., 2012). 
Results from a fuzzy-set analysis of organizational design features associated with high 
enrollment to clinical trials among CCOP organizations indicated that a strategy of having many 
available clinical trials in addition to a large number of patients results in high levels of 
enrollment (Weiner, et. al, 2012). However, the study did not evaluate organizational strategies 
associated with enrollment of minorities in clinical treatment trials. CTOs vary in the 
organizational design features they implement, and it is unknown whether there are consistent 
organizational strategies used by CTOs in order to achieve high enrollment of AA to clinical 
treatment trials.  
The study presented in Chapter 4 focuses on disparities in geographic access to clinical 
trials organizations for populations in the continental United States. In this study, geographic 
access is measured as the travel time from the centroid of ZIP Code Tabulating Areas (ZCTAs) 
in which populations reside, to the nearest clinical trial organizations (CTOs). CTOs include the 
enrolling sites of organizations participating in the NCI’s Community Clinical Oncology 
Program, and hospitals certified by the American Society of Clinical Oncologists Commission 
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on Cancer program. Aim 3 follows on Onega and colleagues (2008) study of geographic access 
to specialized cancer care organizations in the continental US, and employees the geographic 
network approach used in their study. Whereas our study examines disparities in geographic 
access to CTOs (NCI Cancer Centers, CCOPs, MBCCOPs, ACS-COC hospitals), Onega and 
colleagues (2008) study examined disparities in geographic access to specialized cancer care 
organizations, including NCI Cancer Centers, academic medical centers, and community-based 
oncology specialists. Overall, Onega and colleagues’ study estimated that 92% of the US 
population has less than one hour of travel time to any oncologist-based specialty care. The study 
also found that the overall median travel time to NCI Cancer Centers for all demographic groups 
was 78 minutes (Interquartile range, 27-172); and overall median travel time to academic-based 
cancer care organizations is 30 minutes (Interquartile range, 13-72). The study found that 
disparities in geographic access to specialized cancer care organizations for racial and ethnic 
minorities in the US are most pronounced in the regions with large minority populations and 
limited cancer care organizations. With regards to minority populations, Onega and colleagues 
(2008) study found that Asian populations experience the least disparities in geographic access to 
specialized cancer care organizations, whereas Native Americans experience the greatest 
disparities. Black populations in the US tend to reside closer to NCI Comprehensive Cancer 
Centers than white and Hispanic populations; however all ethnic and racial minorities in the 
South experience issues with geographic access to cancer care organizations (Onega, et. al., 
2008). However, Onega and colleagues (2008) study failed to include organizations participating 
in the NCI’s Community Clinical Oncology Program, which may result in the misidentification 
of regions with disparities in geographic access to CTOs. For example, Onega and colleagues’ 
(2008) study found disparities to geographic access to specialty cancer care in the south; their 
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study did not include CCOP, MBCCOP, or all ACOS-COC hospital locations, and 
generalizations about geographic access to CTOs in the south cannot be made. 
The contribution of Aim 3 is significant because it will enhance the ability of NCI, 
AHRQ, existing CTOs, and other organizations to address disparities in geographic access to 
CTOs in the continental US through identification of regions with high travel times to CTOs. 
Research has demonstrated that travel times to cancer organizations is a substantial barrier to 
minority participation in clinical research trials (Holmes JA, et. al., 2012; Ford et. al., 2008; 
UyBico, et. al., 2007); therefore a detailed examination of disparities in minority populations’ 
geographic access to clinical trial organizations is necessary to address overall disparities in in 
clinical research participation. Aim 3 utilizes the network geographic analysis methods employed 
by Onega and colleagues (2008) with additional geocoded data on organizations participating in 
the NCI Community Clinical Oncology Program and the American College of Surgeons 
Commission on Cancer in order to estimate median travel times from ZCTAs to the nearest 
location offering clinical treatment trials (CTO).  
The following three chapters in this dissertation are manuscripts that align with the three 
specific aims and are intended for submission for peer-reviewed publication. The first 
manuscript follows-up on William Carpenter’s analysis (2012) of overall enrollment in clinical 
trials with a focus on black enrollment in clinical treatment trials, and will be submitted to 
Medical Care. The second manuscript is a follow-up to Bryan Weiner’s study (2012) of 
organizational design features of CTOs participating in the Community Clinical Oncology 
Program that result in high overall enrollment to clinical treatment trials, and will be submitted to 
Clinical Trials. The third manuscript follows-up on a study by investigators at Dartmouth 
College that examined geographic access to organizations offering specialized cancer care 
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services in the continental US, and will be submitted to Cancer. Chapter 5 concludes the 
dissertation with a review of the findings from each of the three manuscripts, provides a 
summary of the implications of study findings for policy, practice, and research, and a discussion 
of the limitations of this dissertation. Tables and figures for each manuscript are located at the 
end of each chapter. Finally, additional materials are provided in an Appendix followed by a 
bibliography at the end. 
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CHAPTER 2: IMPACT OF ORGANIZATIONAL CHARACTERISTICS ON 
ENROLLMENT OF BLACK AMERICANS IN CANCER TREATMENT TRIALS  
 
INTRODUCTION 
Disparities in minority participation in clinical research have been long-standing and well 
documented in the US. These disparities are particularly relevant for black Americans1 who have 
the highest cancer mortality rates, poorest survival rates, and the lowest enrollment rates in 
clinical trials, even when compared with other minority groups (Chen, et. al., 2014; Murthy, et. 
al., 2004). Black Americans comprise over 10% of all new cancer cases in the US (US Centers 
for Disease Control), however only an estimated 2-3% participate in clinical treatment trials. 
After more than 20 years since the NIH Revitalization Act mandated the inclusion of minorities 
in NIH funded research, blacks remain disproportionately affected by cancer, and continue to 
experience substantial individual and systemic barriers to participating in cancer clinical trials 
when compared with non-Hispanic whites (Chen, et. al., 2014; Durant, et. al., 2014; Newman, et. 
al., 2008; Stewart, et. al., 2007; Murthy, et. al., 2004; Sateren, et. al., 2002).  
Previous studies have extensively examined individual barriers and facilitators to blacks 
participation in clinical treatment trials;2 however, quantitative studies focused on organizational 
characteristics associated with black enrollment have been limited (Vickers and Fouad, 2014; 
Ford, et. al., 2008). In a recent systematic review of barriers and facilitators to minority 
participation in clinical research, George and colleagues (2014) discuss numerous distinct 
                                                        
1 Black Americans is a heterogeneous racial/ethnic group in the US, but hereafter simplified 
to ‘blacks.’ 
2 Focus of this study is on cancer clinical treatment trials, and hereafter is simplified to ‘trials.’ 
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individual barriers to black participation in trials including: beliefs regarding conspiracies to 
harm blacks; knowledge of the Tuskegee Syphilis study; poor experiences with research staff 
cultural competency; and distrust of health care systems (Murphy and Thompson, 2009; Corbie-
Smith, et. al., 2002; Freimuth, et. al., 2001). Rivers and colleagues’ (2013) systematic literature 
review focusing on factors associated with black participation in trials found similar results, and 
suggested that organizations focusing on targeted enrollment of minorities may be key to 
addressing disparities in trial participation. However, no study has empirically examined the 
impact of organizational characteristics on black enrollment in trials. Empirical studies focusing 
on organizational characteristics associated with black participation in trials have been limited to 
descriptive studies examining mistrust and reputation of research organizations (Murphy and 
Thompson, 2009; Gadegbeku, et. al., 2008; Linden, et. al., 2007; BeLue, et. al., 2006); are 
focused on enrollment to a single trial (Cook, et. al., 2010; Cook, et. al., 2005); or are case 
studies of a single enrolling organization (Holmes, et. al., 2012; Paskett, et. al, 2011; Vicini, et. 
al., 2011; Baquet, et. al., 2006). Studies examining participation of black patients in clinical 
research with multiple organizations did not examine enrollment in trials (Cook et. al., 2010; 
Cook et. al., 2005); or did not include detailed characteristics of the enrolling organizations (Lara, 
et. al., 2005; Murthy, et. al., 2004). Results from other studies have suggested that more 
organizational resources are necessary to establish community support, increase awareness, and 
alleviate barriers to participation (George, et. al., 2014; Ghebre, et. al., 2014; Green, et. al., 2013; 
McCaskill-Stevens, et. al., 2005; Kaluzny, et. al., 1993); and organizations with culturally 
competent members are more likely to enroll blacks and minorities to trials (Durant, et. al., 2014; 
Ejiogu, et. al., 2011; Baquet, et. al., 2006). However, the qualitative approaches and lack of 
empirical studies on modifiable organizational characteristics limits the generalizability of results.  
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The lack of empirical studies of organizational characteristics associated with black 
enrollment in trials limits our ability to develop, implement, and evaluate organizational 
strategies that enhance black participation in trials and address disparities in the receipt of 
innovative cancer therapies. Due to the broad range of barriers to black participation in trials, and 
with the current restructuring of NCI’s clinical trials infrastructure, it is critical that we improve 
our understanding of the organizational characteristics associated with black participation in 
trials in order to address disparities in clinical research participation (Ford, et. al., 2008). The 
objectives of this study are to estimate and evaluate the impact of organizational characteristics 
on enrollment of blacks in NCI-funded trials. To our knowledge, this is the first study that 
empirically estimates the impact of organizational characteristics on enrollment of blacks in trials. 
CONCEPTUAL FRAMEWORK 
This study is informed by the conceptual framework proposed by Ford and colleagues’ 
(2008) systematic review describing barriers and facilitators to minority enrollment in clinical 
research (see Figure 1). Based on their systematic review of the literature framework, enrollment 
of black populations requires awareness of and the opportunity to participate in trials; however, 
barriers and facilitators to acceptance or refusal to enrollment in trials are also particularly 
relevant for the enrollment of black and minority populations. Ford’s model was originally 
proposed to explain individual-level barriers and facilitators to enrolling minority populations in 
trials; however, it strongly suggests pathways in which psychosocial (e.g. culture) and physical 
characteristics (e.g. resources) of an organization can promote awareness of trials, opportunities 
to participate in trials, and facilitate acceptance of an offer to participate in a trial for black 
populations.  
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Organizational characteristics were selected for this study based on their potential impact 
on black populations’ awareness of trials, opportunities to participate in a trial, and acceptance of 
an offer to enroll in a trial. Lack of education about clinical research is the most commonly cited 
barrier to awareness of trials (Ford, et. al., 2008), and previous studies have demonstrated the 
association between education and awareness (Lara, et. al., 2005; Advani, et. al., 2003; Lara, et. 
al, 2001). Formal education regarding clinical research is not commonly provided to populations 
in the US; therefore, implementation of annual CCOP or MBCCOP disparities themed training 
events may be a key organizational characteristic that improves awareness of trials amongst 
black populations. The targeted dissemination of trial information was also cited as a key factor 
in awareness for minority populations; and may be limited by the number of organizations or 
physicians offering trials in regions with specific racial or ethnic backgrounds (Ford, et. al., 
2008). Indeed, studies have identified the impact of the number of enrolling physicians on 
overall enrollment in trials (Carpenter, et. al., 2012), and demonstrated the key role of physicians 
as resources in offering trials to patients (Schmotzer, 2012; Klabunde, et. al., 2011). Therefore, 
we would expect that organizational efforts to increase the number of training events, enrolling 
sites, and enrolling physicians to enhance awareness and result in greater enrollment of blacks in 
trials. 
Organizational characteristics commonly associated with enhanced opportunities to 
participate in trials for black populations include the implementation of policies and procedures 
supporting enrollment and having a large menu of trials for which black patients are eligible. 
Ford and colleagues’ review (2008) found provider attitudes towards trials and the availability of 
appropriate trials for minority populations were frequently reported as key opportunity barriers. 
Organizations may implement supportive policies in order to improve physician attitudes 
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towards enrolling patients in trials such as an expectation for enrolling patients, or providing 
recognition for physicians who enroll patients in trials. Jacobs and colleagues’ (2014) study 
examining the impact of supportive policies on physician enrollment in trials suggests that a 
minimum enrollment expectation and recognition are both positively associated with overall 
enrollment. Whereas the study did not examine black enrollment specifically, we expect 
supportive policies to have the same positive impact on opportunities for black participation.  
With regards to acceptance, the model posits that mistrust in health care systems and 
costs of participation are the most commonly cited barriers to accepting enrollment in a trial. 
Mistrust in health care systems and costs to the patients are commonly cited as barriers to 
acceptance of an offer to participate in literature reviews and supported by qualitative studies 
(Durant, et. al., 2014; Advani, et. al., 2003; Corbie-Smith, et. al., 2002). Therefore, it is expected 
that organizations which serve large minority populations and have tailored strategies for 
enrolling minorities, may be associated with enhanced trust and overall higher enrollment of 
blacks in trials (McCaskill-Stevens, et. al, 2005). Furthermore, additional organizational 
resources such as research staff may be made available to address patient issues with trust; or the 
costs of participating in a trial, and increase the likelihood that black patients will accept an offer 
to participate in a trial (Vickers and Fouad, 2014; Rivers, et. al., 2013).  
The Ford model posits that socioeconomic factors mediate and moderate the impact of 
efforts to enhance awareness and opportunities and to address barriers to accepting participation 
in a trial, and therefore should be included as control variables in quantitative studies of 
enrollment. Studies have found mixed results with regards to the impact of income on enrollment 
in trials (Linden, et. al., 2007; Lara, et. al., 2005; Ford, et. al., 2004; Advani, et. al., 2003); 
however, education, employment, and insurance are key socioeconomic factors associated with 
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black or minority enrollment (Brown and Moyer, 2010; Langford, et. al., 2010; Baquet, et. al., 
2006; Lara, et. al., 2005; Trauth, et. al., 2005; Simon, et. al., 2004; Advani, et. al., 2003; Sateren, 
et. al., 2002). Studies have investigated the impact of competition, managed care, and state-level 
clinical trial insurance mandates on overall enrollment in trials (Carpenter, et. al., 2012; 
Carpenter, et. al., 2006); however, were unable to locate any empirical studies examining the 
impact of competition, managed care penetration, or state insurance coverage mandates on black 
enrollment specifically. 
METHODS 
Setting and Sample Selection 
Since 1983, the NCI Community Clinical Oncology Program has successfully 
demonstrated the ability to implement over 60 provider-based research network organizations 
(PBRNs) in the US including Hawaii and Puerto Rico (Minasian, et. al., 2010; McCaskill-
Stevens, et. al., 2005) (See Map 1). The Community Clinical Oncology Program is comprised 
of: (1) NCI’s Division of Cancer Prevention providing overall direction and funding, (2) Clinical 
Research Group Bases and NCI Cancer Centers designing and developing trials, and (3) the 
PBRN organizations. PBRNs are local networks of community-based oncologists and hospitals 
with the primary goals of: engaging patients in clinical research, disseminating clinical research 
findings into community practice, and enrolling patients in NCI-sponsored clinical trials.  
PBRN organizations in this study are hereafter referred to as “CCOPs;” whereas CCOPs 
that achieve minority-based institutional status based on demonstrated access to a patient 
population comprised of 30% minorities are hereafter referred to as “MBCCOPs.” As of 2014, 
47 CCOPs represent over 300 hospitals and over 3,000 physicians, and 17 MBCCOPs represent 
55 hospitals and approximately 500 physicians. MBCCOPs were implemented beginning in 1990 
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in order to expand the NCI’s efforts to increase minority participation in clinical research. 
MBCCOPs tend to be smaller than CCOPs in terms of enrolling sites, enrolling physicians, 
number of available trials, and number of research staff. Whereas CCOPs may not be lead by a 
university hospital, MBCCOPs tend to be located at universities, or academic medical centers; 
and are in more urban regions (Jacobs, et. al., 2013). The primary tactics MBCCOPs employed 
to enhance minority participation in clinical trials were physician education, and tailored 
community outreach efforts (McCaskill-Stevens, et. al., 2005). Early efforts of the MBCCOPs 
were hindered by the lack of clinically relevant trial protocols, institutional support, and 
community-specific factors (Kaluzny, et. al., 1993). However, the Community Clinical Oncology 
Program has been very successful, resulting in one-third of all patients, and one-fifth of minority 
patients enrolled in NCI-sponsored clinical treatment trials (Minasian, et. al., 2010).  
CCOPs and MBCCOPs actively enrolling patients in trials from 2010-2012 in the 
continental US were included in this study. Each CCOP and MBCCOP was matched to a 
metropolitan statistical area (MSA) and state based on the geographic location of enrolling sites 
per Carpenter and colleagues (2006) in order to allow for the inclusion of independent variables 
that account for differences in demographic characteristics of patient populations.  The analysis 
was restricted to CCOPs and MBCCOPs actively enrolling patients in trials in the continental US 
from 2010-2012 in order to reflect recent trends in clinical research. MBCCOPs located in 
Puerto Rico and Hawaii were excluded from the analysis due to substantially different 
organizational characteristics based on their geographic context (Carpenter, et. al., 2006). The 
final sample includes 45 CCOPs actively enrolling patients from 2010-12, and 13 MBCCOPs in 
2010, increasing to 15 MBCCOPs in 2012; resulting in 177 PBRN-year observations. 
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Descriptive statistics are included for the dependent variable and independent variables in 
Table 1. CCOPs and MBCCOPs vary widely in their organizational characteristics and the 
environments in which they operate. CCOPs are typically larger research organizations than 
MBCCOPs, and have larger numbers of enrolling physicians, research staff, available trials, and 
enrolling sites. Moreover, MBCCOPs typically operate in resource-constrained environments, 
with wide variation in organizational characteristics depending on their organizational structure 
(Kaluzny, et. al., 1993).  
Data Sources 
Data for this study were derived from seven sources. NCI Community Clinical Oncology 
Program annual progress reports provided annual organizational data on CCOP and MBCCOP 
black enrollment to trials and the addresses of CCOP and MBCCOP enrolling locations. A 
survey distributed to CCOP and MBCCOP administrators from 2011-12 as part of another NCI-
funded study (5R01CA124402) supplied additional data on CCOP and MBCCOP organizational 
characteristics in operating year 2011 (annual training events; number of enrolling sites and 
enrolling physicians; enrollment expectation and recognition; number of trials available; and 
number of research staff).  The survey from CCOP and MBCCOP administrators did not collect 
data on CCOP organizational characteristics in 2010 and 2012; however, a 100% response rate 
was achieved, and the organizational characteristics collected typically do not vary from year to 
year (Weiner, et. al., 2012). The American Community Survey provided metropolitan statistical 
area (MSA) demographic data matched to each CCOP and MBCCOP. Kaiser Family Foundation 
(http://kff.org/) supplied state-level data on unemployment, managed care penetration, and 
policies regarding insurance coverage mandates matched to the state where the CCOP/MBCCOP 
headquarters is located. The National Cancer Institute website provided names and addresses of 
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NCI Comprehensive Cancer Centers in the US. The American College of Surgeons (ACoS) 
website provided names and addresses of Commission on Cancer certified hospitals with 
research nurses offering access to clinical trials. Names and addresses of academic medical 
centers in the US were drawn from the Association of American Medical Colleges data on 
Council of Teaching Hospitals members.  
Dependent variable 
The dependent variable of interest in this study is the annual count of black patients 
enrolled in NCI-sponsored trials offered by the sample CCOPs and MBCCOPs. Enrollment in 
trials is the primary measure of performance used by the NCI to evaluate CCOP/MBCCOPs 
PBRNs (Klabunde, et. al., 1994). CCOPs and MBCCOPs have minimum enrollment 
requirements for trials, but do not have specific requirements for the minimum number of black 
patients enrolled. Black enrollment was selected for this analysis rather than minority enrollment 
due to the consistent availability of annual MSA-level community data to control for 
confounding demographic effects. The dependent variable in this study remained in the natural 
count form rather than conversion to a logged form based on the results of Wooldridge tests of 
functional form (Wooldridge, 1994). 
Independent variables of interest 
The independent variables of interest in this study are organizational characteristics of the 
CCOP and MBCCOPs participating in the Community Clinical Oncology Program. These 
variables are intended to capture characteristics that improve awareness of trials, enhance 
opportunities to participate in trials, and promote acceptance of an offer to participate in a trial. 
Organizational characteristics theorized to have a positive impact on awareness include: a 
dichotomous measure for whether the CCOP or MBCCOP organizes annual disparities themed 
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training events; and count measures for the number of sites where patients can enroll in trials and 
the number of physicians enrolling patients for each CCOP or MBCCOP. Organizational 
characteristics theorized to enhance opportunities to participate include a dichotomous variable 
designating an expectation for the physicians to annually enroll a minimum number of patients, 
and a dichotomous designation for CCOP or MBCCOP recognition of physicians’ enrollment in 
trials. Having a large menu of available trials for black populations to be eligible for is also 
expected to improve opportunities for participation in a treatment trial, and is included as the 
count of trials available at each CCOP or MBCCOP. Organizational characteristics expected to 
improve acceptance of an offer to participate include a dichotomous measure for MBCCOP 
status (serving a large minority population), and having a larger number of research staff 
available to help patients navigate the difficulties of participating in a trial. 
Control Variables 
Independent control variables include demographic, and CCOP or MBCCOP market 
characteristics associated with enrollment in trials. Metropolitan statistical area (MSA) total 
black population (in thousands), MSA black uninsured rate, and MSA black unemployment rate 
were included to account for potential demographic confounders in the model (Advani, et. al., 
2003; Sateren, et. al., 2002). State managed care penetration, and a dichotomous measure 
indicating CCOP or MBCCOP situated in states mandating coverage for costs of clinical trials 
(Ellis, et. al., 2012; Gross, et. al., 2005; Gross, et. al., 2004) were included as independent 
variables describing the state environments in which the CCOP and MBCCOPs operate to 
control for endogenous socioeconomic and market factors which may be associated with 
enrollment in trials that have been suggested by previous studies of the Community Clinical 
Oncology Program (Carpenter, et. al., 2012; Carpenter, et. al., 2006). In order to measure 
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competition for trial enrollment, CCOP/MBCCOP organizations, NCI Comprehensive Cancer 
Centers, academic medical centers, and hospitals recognized by American College of Surgeons 
(ACoS) Commission on Cancer that offer NCI trials were identified and geocoded in ArcGIS 
12.1. Fifty-mile buffers were placed on each CCOP/MBCCOP organization, and the number of 
other cancer care organizations unaffiliated with the CCOP/MBCCOP that fell within these 
buffers were identified and tallied in order to generate the measure. Non-affiliated CCOP or 
MBCCOP enrolling locations in the fifty-mile buffers were also included as potential sources of 
competition. An interaction term between minority-based institutional status and MSA black 
population was included in the model to account for MBCCOPs in regions with particularly large 
black populations.  
Analytic Model 
The analysis examined black enrollment in trials using longitudinal, multivariate negative 
binomial count models with standard errors adjusted for clustering at the organizational level. 
Annual CCOP or MBCCOP enrollment of blacks was regressed on the independent variables. 
Skewness and kurtosis tests were used in order to evaluate normality of the error term. A 
common failure of count models is overdispersion, or the assumption that variance is equal to the 
mean (Long and Freese, 2006). Likelihood-ratio tests with a Poisson count model indicated 
overdispersion, and thus a negative binomial count model was selected for final analyses. 
Estimates of marginal and differential effects were analyzed with bootstrapped standard errors 
using 2000 iterations in order to evaluate the impact of organizational characteristics on a CCOP 
or MBCCOP’s annual black enrollment in trials. Analyses were conducted in Stata 12 (StataCorp. 
2009. College Station, TX: StataCorp LP). 
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RESULTS 
Bivariate analyses did not reveal problems with multicollinearity among the selected 
variables (Results available in Appendix). Marginal effects with bootstrapped standard errors for 
the models examining black enrollment in trials are presented in Table 2. Overall, CCOPs and 
MBCCOPs experienced declining enrollment of blacks in trials during the 2010-2012 study 
years. Results suggest that CCOPs and MBCCOPs in the South are associated with greater 
enrollment of blacks when compared with CCOPs and MBCCOPs in the Midwest; whereas 
CCOPs and MBCCOPs in the Northeast and West appear to have lower enrollment compared to 
CCOPs and MBCCOPs in the Midwest.  
Results suggest organizational characteristics vary in their net impact on black enrollment. 
When examining organizational characteristics theorized to promote awareness of trials, a CCOP 
or MBCCOP’s implementation of annual training or education events appears to have a positive 
and significant impact on enrollment. Additionally, the number of enrolling physicians and 
enrolling sites appear to have a positive, but insignificant impact on enrollment. With regards to 
the impact of organizational characteristics on barriers to opportunity to participate in clinical 
trials, an enrollment expectation has a negative and significant impact on black participation in 
trials; whereas recognition for enrolling patients in trials is associated with a positive and 
significant impact on enrollment of blacks for both CCOPs and MBCCOPs. There is a positive 
and insignificant impact of the number of available treatment trials on black enrollment for 
CCOPs and MBCCOPs. Organizational characteristics appear to be associated with a positive 
impact on black Americans’ acceptance of an offer to participate in a clinical trial. Minority-
based institutional status, and the number of research staff both appear to have a positive and 
significant impact on black enrollment in trials.  
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Annual black enrollment ranged from 0 to 63 in the sample (mean = 8.2, standard 
deviation = 10.3), and very few CCOPs and MBCCOPs enrolled more than 12 - 15 blacks to a 
treatment trial. The magnitude of the organizational characteristics on black enrollment also 
varies. The net impact of a training event, or an additional enrolling site or physician is between 
zero and one additional black participating in a treatment trial. An organizational expectation that 
physicians enroll a minimum number of patients appears to have a large negative impact on 
black enrollment. Organizations with enrollment expectations appear to enroll approximately 6 
fewer blacks to treatment trials. Increasing the number of trials each CCOP or MBCCOP has 
available appears to have a negligible impact; however, efforts to provide recognition for 
physician enrollment appears to promote opportunities to participate, and may result in three or 
more black patients enrolling in a treatment trial. Finally, increasing the number of research staff 
may result in reducing barriers to acceptance of offers to clinical trials, but it appears that 
organizations with tailored strategies to serving large minority populations have the largest 
impact on enrollment with 12 additional blacks enrolled by MBCCOPs. 
With regards to the control variables, results indicate that a CCOP or MBCCOPs’ 
proximity to a large black population is associated with a positive and significant impact on 
black enrollment, although the magnitude of the effect is small. Results also indicate that an 
increase in the surrounding region’s proportion of uninsured blacks is associated with a positive 
and significant impact on enrollment. The proportion of blacks attaining a high school diploma, 
and proportion of unemployed blacks also each appear to have a positive impact on enrollment, 
but these results were not significant. Hospital competition has a positive and significant impact 
on enrollment. State managed care penetration has a positive and significant impact; and a state 
insurance coverage mandate to cover the costs of trials also appears to have a positive and 
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significant impact on enrollment. The interaction terms between MBCCOP status and MSA 
black population is statistically significant; and the parameter coefficients included in Table 2 
include the partial effect of the interaction since we sought to estimate marginal effects, and 
therefore analyzed the net impact of each organizational characteristic on black enrollment.  
Sensitivity Analyses 
 In order to evaluate model fit and omitted variable bias, we conducted two sensitivity 
analyses. First, our analytical dataset included 24 (13.6%) observations with zero enrollments of 
blacks to trials. Zero-inflated negative binomial (ZINB) models are often used to account for 
excessive zeros in the dependent variable (Long and Freese, 2006). A ZINB model utilizes 
maximum likelihood estimates that are approximately normal in large samples, with standard 
errors and confidence intervals constructed to account for possible processes that result in a zero 
dependent variable (Cameron and Trivedi, 2010). The a priori assumption underlying the ZINB 
model lies in the probability that observations with a zero count are fundamentally different from 
other observations. Specifically, there is a 100% probability of always having a zero count for 
some of the observations. This requires the use of a separate modeling process predicting an 
outcome with a zero count. This study utilized the proportion of blacks in the MSA to explain 
observations that would have 100% probability of having zero enrollments of blacks. Standard 
and bias-corrected Vuong tests were used to compare negative binomial and zero-inflated 
negative binomial models, and results from each test indicated a better fit with the negative 
binomial model (Desmarais and Harden, 2013). 
 Our model included MSA-level measures of black high school attainment and uninsured 
rates; and state-level unemployment due to lack of full unemployment data at the MSA level to 
account for confounding effects of socioeconomic conditions on black enrollment. A direct 
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measure of black wealth was not included in the original analysis due to the correlations between 
income, education, insurance, and unemployment. Moreover, a parsimonious selection of 
variables was included due to the small sample size of CCOPs and MBCCOPs. Since it is 
unclear if wealth is an endogenous factor in our model (Rivers, et. al., 2013; Baquet, et. al., 
2006; Sateren, et. al., 2002), we collected data on median family wealth from U.S. Census 
American Community Survey 3-year estimates and added this variable to a post-hoc regression 
analyses to investigate potential omitted variable bias. Whereas MSA median black family 
income has very little impact on enrollment, and is not statistically significant, its inclusion in the 
model results in changes to other parameters, indicating model instability. The Bayesian 
Information Criteria (BIC) goodness-of-fit measure for the model including MSA black family 
wealth is slightly higher than the model that does not include it, and the difference between the 
pseudo R2 for the models is very small. Overall, the impact of the potential model instability on 
the organizational characteristics is negligible, but including family wealth appears to have a 
substantial impact on the environmental variables. Based on preliminary analyses using black 
enrollment data from 2000-2008, this model instability may be due to a failure to include key 
interactions between organizational or environmental variables. For example, preliminary 
analyses indicated a statistically significant interaction between MSA black education and 
unemployment. These measures are likely highly correlated at the individual level; however 
bivariate analyses do not indicate a high degree of correlation between these two MSA-level 
variables, and were not included as an interaction term in the final model for lack of theory 
guiding the interaction, and parsimony. 
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DISCUSSION 
This study focused on the impact of organizational characteristics on enrollment of blacks 
in clinical treatment trials sponsored by PBRNs participating in the NCI Community Clinical 
Oncology Program from 2010-2012. Overall, our analysis provides support for Ford’s 
conceptual framework, and demonstrates that organizational characteristics do have an impact on 
the enrollment of black patients in trials. This is the first study to find empirical support for the 
implementation of organizations with tailored strategies for serving minority populations on 
enrolling black patients using a multivariate statistical approach and detailed longitudinal data on 
organizations. On average, MBCCOPs enroll approximately 13 more blacks to trials than CCOPs. 
This may not appear a large number; however, this is no small number for an organization to 
enroll when considering the complexities of opening trials, and the multitude of individual-level 
barriers to black participation in clinical research (Chun & Park, 2012; Adams-Campbell, et. al., 
2004). Therefore, our study suggests that policies further supporting the implementation of 
minority-focused clinical trials organizations may be critical to improve black participation in 
clinical research. 
Whereas organizational characteristics appear to have an impact on black enrollment, it is 
important to note that few of the key modifiable organizational characteristics in our study 
appear to have large net substantial impact on black enrollment. For example, implementing an 
annual training event; or increasing the number of enrolling sites or physicians in order to 
increase awareness of clinical trials appear to result in small average gains in black enrollment 
(i.e. less than one). This is consistent with findings from Lara and colleagues (2005) study of 
cancer patients that strongly suggested the importance of awareness improvement activities 
alongside other activities to improve participation of blacks in clinical research. However, it 
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appears that organizational characteristics theorized to address opportunity barriers to enrollment 
have a larger net impact. For example, providing tokens of recognition to physicians for 
enrolling patients may result in three or more black patients participating in trials annually. 
Implementing an enrollment expectation among physician appears to have a negative impact on 
black enrollment in trials. This was an interesting finding in light of recent research 
demonstrating the impact of an expectation on individual-enrollment in clinical trials for all 
populations (Jacobs, et. al., 2014). We expect this is due to a subset of CTOs that have adopted 
strategies aimed at efficiently enrolling large number of patients. These “efficiency-oriented” 
CTOs typically do not open trials that are clinically relevant for minority populations; and more 
importantly, also implement an enrollment expectation as an approach to efficiently recruiting 
large numbers of overall patients to treatment trials. Considering findings from Jacobs and 
colleagues’ (2014) study, additional analyses may be necessary to understand the impact of 
expectations on overall trial enrollment versus minority trial enrollment. For example, a certain 
type of CCOP may enroll large numbers of blacks in trials with an enrollment expectation in 
combination with other organizational characteristics. 
Despite the overall low net impact of many organizational characteristics, post-hoc 
analyses suggest that combinations of organizational characteristics are associated with enhanced 
participation of blacks in trials, regardless of the size or characteristics of the black population 
served. For example, estimates suggest that a CCOP in a state that mandates insurance coverage 
of trial costs, in a region with approximately 400,000 blacks, which implements an enrollment 
expectation and annual disparities training events, and also recognizes physician enrollment will 
result in an average annual enrollment of 20 black patients. That is a substantial number of 
blacks enrolled when compared with the average impact of minority-based institutional status of 
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a PBRN; and is particularly relevant for organizations located in regions with sizable black or 
minority populations. This suggests that while MBCCOPs may have an edge in enrollment of 
black patients, non-minority focused organizations can employ strategies capable of enrolling 
blacks in clinical treatment trials. For example, in addition to promoting the development of 
MBCCOPs, promoting the development of focused research staff at CCOPs that are dedicated to 
enhancing minority participation may be an effective overall strategy for addressing barriers 
(Rivers, et. al., 2013; Vicini, et, al., 2011; Ford, et. al., 2008).  
The positive and significant impact on enrollment of the number of other cancer care 
organizations in a CCOP or MBCCOP’s region suggests that nearby hospitals do not compete for 
black enrollment. Results from our study differ from previous studies on competition, which 
found that CCOPs had lower overall trial enrollment in communities with a larger presence of 
hospitals affiliated with a medical school (Carpenter, et. al., 2011). MBCCOPs are typically 
housed in, or closely affiliated with, an academic medical center. Thus, our findings may reflect 
the predominance of minority enrollment in academic organizations in regions with overall 
larger number of hospitals. Combined, these factors suggest that in order to enroll greater 
numbers of blacks to treatment trials, it may be appropriate to have both an MBCCOP and 
CCOP; or a CCOP with specific physicians and staff dedicated to enhancing minority 
participation located in regions with large minority populations. 
Whereas our analysis demonstrates that organizational characteristics can have an impact 
on enrollment of blacks to trials, it appears that environmental factors are still important. We 
found that state policies mandating insurance coverage of clinical trial costs are associated with a 
positive and significant impact on black enrollment. This supports previous studies indicating 
that black patients may be particularly sensitive to the costs of participation in trials (Ford, et. al., 
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2008), however, differs from a previous study on the impact of state insurance coverage 
mandates on minority trial participation (Chun & Park, 2012). However, the previous study 
examined enrollment of minorities from 2001-2007, which may have not have been enough time 
for policies regarding insurance coverage to have an impact on minority enrollment. Moreover, 
our study examined enrollment from 2010-2012, and our results may reflect the long-term 
impact of policies mandating coverage of clinical trials costs for minority populations.  
Our study demonstrates that the environment in which CTOs operate are important for 
enrollment; however, we compared the pseudo R2 and BIC scores from our final model, and a 
model excluding organizational characteristics in post-hoc analyses. Estimates suggest that a 
model with only environmental variables explains approximately 9% of the variation in black 
enrollment in treatment trials (Appendix), whereas the model that includes organizational 
characteristics explains approximately 16% of the variation. Additionally, the BIC score for the 
model without organizational characteristics is greater than the BIC for the model with 
organizational characteristics, indicating superior goodness-of-fit. However, based on results 
from post-hoc analyses, we urge caution in considering the net impact of an organizational 
characteristic on black enrollment in trials when it is possible that multifaceted strategies, 
comprised of combinations of tactics employed in specific environments, are responsible for 
high organizational enrollment of blacks to trials.  
There are several limitations to this study. The relatively small sample of CCOPs and 
MBCCOPs is a limitation to the generalizability of our results to other clinical trials 
organizations. However, we are unaware of a larger sample of organizations enrolling blacks in 
clinical trials, and the organizations in this study vary substantially in their organizational 
characteristics. Furthermore, this study is strengthened by its longitudinal design, inclusion of 
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regional demographic data, and detailed organizational characteristics. Additionally, there is a 
potential limitation in using spatially aggregated MSA variables in this analysis, including the 
potential for ecological fallacy if CCOPs and MBCCOPs operating environments are not 
accurately characterized by the MSAs in which they are located (Portnov, et. al., 2007; 
Openshaw, 1984). For example, hospital referral region data may reflect more accurately the 
demographics and market characteristics of each PBRN; however, those data were not available 
for the years of this study.  
CONCLUSION 
It is unclear how the reorganization of NCI’s infrastructure, and changes in health care 
markets as a result of states implementing health reforms will impact CCOPs and MBCCOPs. 
Findings from this study demonstrate that minority-based PBRNs make sense. Our study also 
suggests that strategic combinations of characteristics may be implemented by minority-based 
and non-minority based organizations in order to address barriers to awareness, opportunity, and 
acceptance of clinical trials and enhance black participation in clinical research. Recent research 
has demonstrated the importance of specific combinations of organizational characteristics 
resulting in high performing clinical trials organizations. However, those studies failed to 
examine strategies resulting in minority participation in treatment trials; therefore, additional 
research is necessary to examine the organizational strategies that CCOPs and MBCCOPs 
implement in order to enroll blacks and other minorities in trials. 
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Figure 1. Aim 1 Conceptual Framework (Ford, et. al., 2008) 
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Table 1. Descriptive Statistics of Analytical Sample 
 
 
     Standard 
Variables     Mean  Min/Max  Deviation 
Dependent Variables  
   African American enrollment   8.51  0/63   10.32 
Independent Variables 
   Minority-based Institutional Status  24.3% 
   No. of Enrolling Physicians   40.08  3/209   34.44 
   No. of Research Staff    14.58  2/77.7   12.35 
   No. of Treatment Trials Available  32.88  3/79   16.37 
   No. of Enrolling Sites    7.70  1/28   5.72  
   Enrollment Expectation    32.2% 
   Recognition     47.5% 
   No. Training Events    1.83  0/13   3.51  
   Black MSA population    401,909  655/2,613,412  681,989 
   Proportion MSA Black High School Grad 
   Proportion MSA Black Uninsured  0.178  0.063/0.312  0.040 
   Proportion MSA Black Unemployment  0.160  0.006/0.247  0.038 
   Hospital Competition    27.88  0/94   25.96 
   State HMO Penetration    0.184  0.025/0.435  0.093 
   State Insurance Coverage Mandate  62.1% 
   Census Region Northeast   15.0% 
   Census Region South    26.7% 
   Census Region Midwest    45.0% 
   Census Region West    13.3% 
   Year 2010     32.8% 
   Year 2011     33.9% 
   Year 2012     33.3% 
 
    
    
   
    
 
 
  
 
Figure 2. NCI Cancer Centers, CCOPs/MBCCOPs, Commission on Cancer Hospitals, 
Academic Medical Centers 
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Table 2. Regression Results: Impact of Organizational Factors on 
Enrollment of Blacks in Cancer Clinical Treatment Trials 
   
     
Variable 
Marginal 
Effects 
Standard 
Error♯ P-value 
95% Confidence 
Interval 
Number of Training Events 0.496*** 0.194 0.011 0.116 0.876 
Number of Enrolling Sites 0.159 0.191 0.403 -0.214 0.533 
Number of Enrolling Physicians 0.035 0.030 0.253 -0.025 0.094 
Enrollment Expectation -6.623*** 2.022 0.001 -10.585 -2.661 
Enrollment Recognition 2.319 1.689 0.170 -0.992 5.631 
Number of Treatment Trials Available 0.073 0.093 0.429 -0.108 0.255 
MBCCOP 11.323** 5.165 0.028 1.199 21.466 
CCOP - - - - - 
Number of Research Staff 0.260** 0.113 0.022 0.038 0.483 
MSA Black Population (1000s) 0.004** 0.002 0.012 0.001 0.008 
MSA Proportion Black High School 
Graduates 18.209 23.974 0.448 -28.780 65.197 
MSA Proportion Black Uninsured 68.679** 34.633 0.047 0.799 136.558 
MSA Proportion Black Unemployed -1.697 31.980 0.958 -64.376 60.982 
Hospital Competition 0.219*** 0.055 0.000 0.111 0.328 
State Managed Care Penetration 17.454 14.094 0.216 -0.181 45.078 
State Insurance Coverage Mandate 3.335* 1.793 0.063 -0.181 6.850 
Northeast -2.775 2.999 0.355 -8.654 3.105 
South 7.799*** 2.845 0.006 2.222 13.377 
West -4.756*** 1.769 0.007 -8.223 -1.289 
Midwest - - - - - 
2010 - - - - - 
2011 -1.167 1.213 0.336 -3.543 1.209 
2012 -2.193 1.331 0.100 -4.802 0.417 
n = 172 
     Pseudo R2 = 0.1556; BIC = 1059.52 
     * p < 0.10; ** p < 0.05; *** p < 0.01 
      Bootstrapped Standard Errors (2000 
replications) 
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Table 3. ZINB Regression Results: Impact of Organizational 
Factors on Enrollment of Blacks in Cancer Clinical Treatment 
Trials 
   
     
Variable 
Marginal 
Effects 
Standard 
Error♯ P-value 
95% Confidence 
Interval 
Number of Training Events 0.397 0.301 0.188 -0.193 0.986 
Number of Enrolling Sites 0.307** 0.140 0.028 0.033 0.580 
Number of Enrolling Physicians 0.019 0.021 0.383 -0.024 0.062 
Enrollment Expectation -3.768 1.950 0.053 -7.589 0.054 
Enrollment Recognition 1.812 2.289 0.428 -2.673 6.298 
Number of Treatment Trials Available 0.083 0.058 0.153 -0.031 0.196 
MBCCOP 8.606* 5.145 0.094 -1.479 18.690 
CCOP - - - - - 
Number of Research Staff 0.165** 0.078 0.036 0.010 0.318 
MSA Black Population (1000s) 0.026** 0.009 0.003 0.009 0.042 
MSA Proportion Black High School 
Graduates 8.776 22.887 0.701 -36.081 53.633 
MSA Proportion Black Uninsured 58.928 42.460 0.165 -24.291 142.148 
MSA Proportion Black Unemployed -7.961 37.631 0.832 -81.717 65.795 
Hospital Competition 0.166*** 0.047 0.000 0.747 0.257 
State Managed Care Penetration 21.518 14.121 0.128 -6.160 49.195 
State Insurance Coverage Mandate 1.987 2.089 0.341 -2.107 6.081 
Northeast -2.259 3.425 0.510 -8.972 4.454 
South 4.424 3.022 0.143 -1.498 10.347 
West -5.242*** 3.022 0.004 -8.799 -1.685 
Midwest - - - - - 
2010 - - - - - 
2011 -0.851 0.832 0.307 -2.482 0.780 
2012 -1.931*** 0.936 0.039 -3.766 -0.097 
n = 172 
     Pseudo R2 = 0.1220; BIC = 1055.52 
     * p < 0.10; ** p < 0.05; *** p < 0.01 
      Bootstrapped Standard Errors (2000 
replications) 
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Table 4. Regression Results: Impact of Organizational Factors on 
Enrollment of Blacks in Cancer Clinical Treatment Trials 
   (Add MSA Median Black Family Income) 
 
    
Variable 
Marginal 
Effects 
Standard 
Error♯ P-value 
95% Confidence 
Interval 
Number of Training Events 0.617*** 0.202 0.002 0.221 1.013 
Number of Enrolling Sites 0.226 0.171 0.187 -0.11 0.562 
Number of Enrolling Physicians 0.039 0.028 0.164 -0.016 0.093 
Enrollment Expectation -6.295*** 1.899 0.001 -10.016 -2.573 
Enrollment Recognition 2.815* 1.699 0.097 -0.514 6.145 
Number of Treatment Trials Available 0.065 0.082 0.427 -0.095 0.225 
MBCCOP 10.293** 5.061 0.042 0.373 20.213 
CCOP - - - - - 
Number of Research Staff 0.231** 0.097 0.017 0.041 0.421 
MSA Black Population (1000s) 0.005** 0.002 0.031 0 0.01 
MSA Proportion Black High School 
Graduates 19.76 29.105 0.497 -37.285 76.805 
MSA Proportion Black Uninsured 77.209** 34.555 0.025 9.482 144.935 
MSA Proportion Black Unemployed 2.645 37.841 0.944 -71.523 76.813 
MSA Median Black Family Income -0.0001 0 0.654 -0.001 0 
Hospital Competition 0.139*** 0.047 0.003 0.046 0.232 
State Managed Care Penetration 27.377* 14.911 0.066 -1.849 56.603 
State Insurance Coverage Mandate 2.097 1.698 0.217 -1.231 5.425 
Northeast -4.384 2.841 0.123 -9.953 1.184 
South 4.768** 2.345 0.042 0.173 9.364 
West 
-
5.0899*** 1.558 0.001 -8.144 -2.036 
Midwest - - - - - 
2010 - - - - - 
2011 -0.813 1.16 0.483 -3.086 1.46 
2012 -2.063 1.231 0.094 -4.476 0.35 
n = 172 
     Pseudo R2 = 0.1573; BIC = 1065.76 
     * p < 0.10; ** p < 0.05; *** p < 0.01 
      Bootstrapped Standard Errors (2000 
replications) 
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CHAPTER 3: A FUZZY-SET ANALYSIS OF ORGANIZATIONAL STRATEGIES 
PROMOTING MINORITY PARTICIPATION IN CANCER TREATMENT TRIALS 
 
INTRODUCTION 
 
More than 20 years since the NIH Revitalization Act mandated the inclusion of 
minorities in NIH funded research, minorities remain disproportionately affected by cancer, and 
continue to be underrepresented in cancer clinical trials when compared with non-Hispanic 
whites (Chen, et. al., 2014; Durant, et. al., 2014; Newman, et. al., 2008; Stewart, et. al., 2007; 
Murthy, et. al., 2004; Sateren, et. al., 2002). Overall, less than 3% of adult cancer patients 
participate in trials, and minority populations represent less than 0.3% of participants (Vickers 
and Fouad, 2014; Stewart, et. al., 2007). Moreover, research has also found an overall decline in 
the proportion of minorities participating in clinical trials (Heller, et. al., 2014; Kwiatkowsky, et. 
al., 2013; Newman, et. al., 2008).  
For more than 30 years, the National Cancer Institute’s Clinical Oncology Program has 
enrolled patients in clinical trials through the implementation of provider-based research network 
(PBRN) organizations in community-based settings. These PBRN organizations are hereafter 
referred to as “CCOPs,” or “MBCCOPs” for minority-based CCOPs, which specialize in serving 
minority populations.  CCOPs and MBCCOPs are collaborations between academic-based 
physicians and oncology physicians in community-based hospitals and private practices. CCOPs 
and MBCCOPs have been very successful, resulting in one-third of all patients, and one-fifth of 
minority patients enrolled in NCI-sponsored clinical treatment trials (Minasian, et. al., 2010). 
Systematic reviews of minority participation in clinical research reveal extensive research on 
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patient and provider-level barriers to participation in clinical trials; however, studies focusing on 
organizational strategies to enroll minority populations in clinical treatment trials are limited. 
(George, et. al.2014; Schmotzer, 2012; Ford et. al., 2008; Howerton, et. al., 2007). Barriers to 
participation include lack of provider awareness of locally available trials, unfavorable provider 
attitudes, patient mistrust and limited geographic access (George, et. al., 2014; Schmotzer, 2012; 
Ford, et. al. 2008; Lara, et. al., 2001). Unfortunately, empirical studies focusing on strategies 
associated with minority participation in clinical trials have been limited to descriptive studies 
examining organizational staffing and resource barriers (McCaskill-Stevens, et. al., 2006; 
Adams-Campbell, et. al., 2004); and single site case studies of minority outreach or patient 
navigator programs (Holmes, et. al., 2012; Paskett, et. al, 2011; Vicini, et. al., 2011). Specific 
studies on CCOPs and MBCCOPs suggest that enrollment of patients in clinical trials varies with 
certain organizational strategies, comprised of tactics (Weiner, et. al. 2012; Teal, et. al. 2012; 
Clauser, et. al., 2009; McKinney, et. al., 2006; Weiner, et. al., 2006; Kaluzny, et. al., 1989). In 
this study, tactics are the organizational characteristics implemented by CTOs such as training 
events, or a large research staff. For example, studies examining specific tactics resulting in high 
minority enrollment have suggested community-based participatory research approaches, 
outreach, and trainings (Vicini, et. al., 2011), or patient navigation programs (Holmes DR, et. al., 
2012) are associated with greater enrollment of minorities in treatment trials. Results from a 
fuzzy-set analysis of strategies associated with high levels of overall enrollment in clinical 
treatment trials among CCOP organizations indicated that the number of new patients, the 
number of available treatment trials, and the number of enrolling sites are key tactics in 
achieving high levels of enrollment (Weiner, et. al, 2012). However, the study did not examine 
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strategies or tactics consistently associated with high enrollment of minorities in clinical 
treatment trials.  
This gap in the research limits our ability to develop, implement, and evaluate strategies 
in order to improve minority participation in clinical treatment trials. The aim of this study is to 
examine the organizational strategies and tactics implemented by CCOPs and MBCCOPs that 
result in high organizational enrollment of minority populations in NCI-sponsored clinical 
treatment trials. In order to accomplish this aim, we collected detailed organizational data on 
CCOPs and MBCCOPs actively enrolling patients in clinical trials from 2010-2012; and 
employed a novel method, fuzzy-set qualitative comparative analysis to investigate the tactics, 
and combinations of tactics that lead to high organizational enrollment of minorities to treatment 
trials. Fuzzy-set qualitative comparative analysis (fsQCA) is used for this study based on results 
from a multivariate analysis of organizational characteristics suggesting that CCOPs and 
MBCCOPs may achieve high enrollment of minorities in trials based on the impact of 
combinations of organizational characteristics  (Belden, et. al., dissertation chapter 2 – 
manuscript 1). Moreover, fsQCA is particularly appropriate when an outcome of interest (high 
organizational enrollment of minorities to treatment trials) may be the result of varying strategies, 
which are themselves combinations of different tactics. To our knowledge, this is the first study 
to empirically examine the tactics that CCOP and MBCCOP organizations implement in order to 
enroll high numbers of minorities to clinical treatment trials.  
METHODS 
 
Study Setting 
This study focuses on provider-based research network (PBRN) organizations 
participating in the National Cancer Institute Community Clinical Oncology Program. PBRNs 
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are local networks comprised of community-based oncologists and hospitals. The primary goals 
of CCOPs and MBCCOPs are: engaging physicians in clinical research, disseminating clinical 
research findings into community practice, and enrolling patients in NCI-sponsored clinical trials.  
Since 1983, the NCI Community Clinical Oncology Program has successfully demonstrated the 
ability to effectively implement over 60 PBRNs in communities across the US (Minasian, et. al., 
2010). The Community Clinical Oncology Program is comprised of: (1) NCI’s Division of 
Cancer Prevention which provide overall direction and funding, (2) Clinical Research Group 
Bases and NCI Cancer Centers which design and develop clinical trials, and (3) the PBRN 
organizations which enroll patients. As of June 2013, 47 CCOPs represent 340 hospitals and 
nearly 3,000 physicians; and 16 MBCCOPs represent 55 hospitals and nearly 500 physicians.  
Data Measures and Sources 
The outcome of interest for this study, high organizational enrollment of minorities in 
trials, is based on the total annual count of non-white patients CCOPs and MBCCOPs enrolled in 
clinical treatment trials from 2010-2012. Enrollment in treatment trials is the primary measure of 
performance for CCOPs and MBCCOPs. MBCCOPs are required to serve a population 
comprised of a minimum of 40% minorities (McCaskill-Stevens, et. al., 2005); but do not have a 
minimum requirement for minority enrollment.  Both CCOPs and MBCCOPs however do have 
minimum requirements for overall enrollment in treatment trials. Annual data on the number of 
minority patients enrolled in clinical treatment trials by CCOP and MBCCOP organizations were 
drawn from the NCI Community Clinical Oncology Program annual program reports. NCI 
Division of Cancer Prevention officials established the threshold for high minority enrollment in 
treatment trials as described below. 
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CCOP and MBCCOP tactics were drawn from a survey of CCOP and MBCCOP program 
administrators conducted from 2011-2012. The CCOP Administrator Survey aimed to examine 
how CCOPs and MBCCOPs operate.  Data were gathered from 100% of active CCOPs and 
MBCCOPs. The survey gathered detailed information on tactics including: MBCCOP status, the 
number of enrolling physicians, number of research staff, number of available treatment trials, 
number of enrolling sites, number of enrolling sites with screening and/or staff assistance with 
enrollment, enrollment expectation, recognition for enrollment, and annual training events. 
Study Design and Data Analysis 
 
Fuzzy-set qualitative comparative analysis (fsQCA) was used to examine the strategies, 
comprised of multiple tactics implemented by CCOPs and MBCCOPs, that consistently achieve 
high organizational enrollment of minority patients in clinical treatment trials. FsQCA is a case 
study approach used to investigate logical relationships between causal conditions (e.g. tactics), 
and an outcome of interest using set theory. Statistical approaches can be used to estimate the net 
impact of a causal condition on an outcome of interest; however, the assumptions required for 
unbiased estimates with statistical approaches may not hold with small sample sizes. For 
example, omitted variables may introduce substantial bias in statistical approaches. The strength 
of the fsQCA approach is the examination of causal conditions (e.g. tactics) that are individually 
necessary or sufficient for an outcome of interest (e.g. high minority enrollment); and to 
investigate the combinations of causal conditions (e.g. strategies) that are sufficient for the 
outcome of interest (e.g. high minority enrollment) in small samples (Kane, et. al., 2014; Longest 
and Thoits, 2012; Ragin, 2000; Ragin, 2008). Moreover, the fsQCA approach allows an 
examination of the organizational tactics (i.e. characteristics) implemented by CTOs that enroll 
large numbers of minorities to clinical trials without meeting the strict assumptions necessary for 
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statistical approaches. This is particularly appropriate in this analysis with 62 CCOPs and 
MBCCOPs under study. 
The fsQCA approach examines set, subset, and superset relationships between causal 
conditions (e.g. organizational tactics) and the outcome of interest (high minority enrollment). 
Causal conditions, or combinations of causal conditions, that are always required for an outcome 
of interest demonstrate a superset relationship with the outcome set, and are considered 
necessary for the outcome of interest. Causal conditions, or combinations of causal conditions, 
that frequently result in the outcome of interest and demonstrate subset relationships with an 
outcome set, are considered sufficient to achieve the outcome. A set-theoretical underpinning of 
fsQCA is equifinality, which proposes that multiple combinations of causal conditions (e.g. 
tactics) can lead to the same outcome of interest (e.g. membership in the set of CCOPs or 
MBCCOPs with high organizational enrollment of minorities in treatment trials). (Goertz and 
Mahoney, 2005; Ragin, 2000; Ragin, 2008). Furthermore, set theory allows us to logically 
assume that strategies resulting in high minority enrollment may contain different combinations 
of tactics. For example, set theory allows for the explanation that one strategy resulting in high 
minority enrollment includes a large number of physicians with a large menu of trials, and many 
enrolling sites with screening assistance; whereas another strategy resulting in high minority 
enrollment includes a small number of physicians who receive assistance with enrollment at 
many sites, and an annual training event.  
FsQCA has been previously used to identify organizational strategies resulting in overall 
high enrollment of patients to treatment trials (Weiner, et. al., 2012). This fsQCA examined the 
necessary tactics, and sufficient strategies resulting in high minority enrollment. The analysis 
was completed in 7 steps: 1) Calibrate crisp and fuzzy membership scores; 2) Construct a truth 
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table, a matrix containing the fuzzy and crisp membership scores in the outcome and condition 
sets; 3) Examine necessity of tactics with consistency scores; 4) Logical minimization of 
redundant cases with Quine-McCluskey algorithm; 5) Assess sufficiency of organizational 
strategies with consistency scores, and inclusiveness; 6) Examine the empirical relevance of 
organizational strategies with coverage scores; 7) Counterfactual analysis of organizational 
strategies.  
A key step in the fsQCA approach is calibration, or the decision rules for establishing 
membership scores in causal condition and outcome sets. Membership scores in fsQCA vary 
from 0.0 to 1.0, and are categorized as crisp or fuzzy. Membership in a crisp set is similar to a 
dichotomous variable: a case has full membership in the causal condition, or has full non-
membership in the causal condition. For example, if an organization meets the criteria outlined 
by the NCI as a minority-based institution, it would receive a membership score of ‘1’ in the set 
of MBCCOPs; if the organization does not meet the criteria, it is not an MBCCOP and would 
receive a crisp membership score of ‘0,’ and thus have full non-membership in the set of 
MBCCOPs. Fuzzy membership scores range from 0.0 to 1.0 in order to allow for finer gradients 
of membership in a set. The use of external standards such as expert judgment, theoretical 
knowledge, and prior research findings is the preferred approach for developing decision rules 
for anchor points for full membership in a set, full non-membership in a set, and a cross-over 
point indicating maximum ambiguity of membership in a set (Ragin, 2008; Ragin, 2000). For 
example, an MBCCOP may have a fuzzy membership score that indicates it is fully in the 
outcome set of organizations achieving high minority enrollment; the MBCCOP may have a 
fuzzy membership score indicating it is not in the set of organizations achieving high minority 
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enrollment; or the MBCCOP has a fuzzy membership score indicating it is ambiguous as to 
whether it is fully in or out of the set of organizations achieving high minority enrollment. 
 To prepare fuzzy set membership scores, expert opinion was sought from NCI Division 
of Cancer Prevention officials to establish anchor points indicating full membership, full non-
membership, and a cross-over point of maximum ambiguity for the following study measures: 
minority-enrollment, number of enrolling locations, number of physicians enrolling, number of 
trials available, and the number of research staff at each CCOP and MBCCOP. Based on 
substantive knowledge, and discussions with NCI officials, different anchor points were 
developed to account for differences in the actual sizes of CCOP and MBCCOP organizations. 
The anchor points established by NCI Division of Cancer Prevention officials were also used in 
order to transform the measures for number of screening sites, and the number of sites with 
enrollment assistance, into fuzzy set membership scores. Fuzzy membership scores for sites with 
screening and sites with enrollment assistance were standardized for each CCOP and MBCCOP 
using the total number of enrolling locations, and then re-scaled using the anchor points 
suggested by NCI officials. Anchor points for CCOP and MBCCOP tactics are listed in Table 6. 
Additional study measures were dichotomous, and included in the fsQCA analysis as crisp 
membership scores. A crisp membership score is either one or zero, with one indicating full 
membership in the set of interest (e.g. PBRNs serving a large minority population and 
categorized as MBCCOPs), and zero indicating full non-membership in the set of interest (e.g. 
PBRNs that do not serve large minority populations, and are categorized as CCOPs). The 
following study measures are crisp: MBCCOP, enrollment expectation, enrollment recognition, 
feedback on overall organizational enrollment, feedback on individual physician enrollment, and 
whether the CCOP or MBCCOP implemented annual training events. 
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 After fuzzy-set membership scores were calibrated, a data matrix was created each of the 
CCOP and MBCCOP case strategies. The data was then reduced by eliminating strategies that do 
not consistently result in high minority enrollment by removing rows with a fuzzy membership 
score greater than 0.5 in the set of PBRNS with high minority enrollment in treatment trials. 
Further minimization of the remaining cases in the truth table was based on three criteria:  (1) the 
minimum number of cases for inclusiveness; (2) the minimum consistency of a strategy; and 3) 
the Quine-McCluskey algorithm derived from Boolean Algebra was used in order to eliminate 
redundant organizational strategies. Inclusiveness is selected as the minimum number of cases 
required in order to identify a set of conditions that lead to the outcome of interest. Due to the 
moderately small number of organizations in the study (N=63), the minimum number of cases 
will be set equal to one as proposed by Ragin (2008). Thus, strategies that did not exhibit an 
empirical case were used in the counterfactual analysis. Consistency is used to evaluate the 
frequency with which cases result in the outcome of interest. Consistency is measured as (Xi ≤ Yi) 
= ∑[min(Xi, Yi]/ ∑(Xi), where X is the fuzzy-set membership score in a set for an organizational 
strategy and Y is the fuzzy-set membership score in the set for high minority enrollment. As 
suggested by Ragin (2008) and Weiner’s (2012) analyses, the minimum acceptable consistency 
threshold is set at 0.80 (Ragin, 2008). Final minimization of the data matrix into a truth table 
used Boolean algebra and the Quine-McCluskey algorithm to logically minimize organizational 
strategies that are sufficient for achieving high minority enrollment (Ragin, et. al. 2008). The 
truth table contains 2k rows, where k is the number of tactics included in the analysis, and 
includes the score in the outcome set of interest (Ragin, 2008). 
The final truth table was used to examine the empirical relevance of each of the logical 
organizational strategies that consistently result in high enrollment of minorities in treatment 
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trials with coverage scores. Coverage is a proportional measure describing the degree of overlap 
among two or more combinations of tactics (Ragin, 2008). Coverage evaluates the frequency 
with which a strategy results in the outcome of interest, and is measured as (Xi ≤ Yi) = ∑[min(Xi, 
Yi]/ ∑(Yi), where X is the fuzzy-set membership score in a set representing a strategy, and Y is 
the fuzzy-set membership score in the set for high minority enrollment. Raw coverage 
A counterfactual analysis was used to examine the strategies that lead to high minority 
enrollment that lack empirical cases. This approach specifically allows for investigation of 
strategies that are theoretically or empirically suggested to result in high minority enrollment; 
and may lead to further reduction of organizational strategies that require further study (Ragin, 
2008; Weiner, et. al., 2012). The counterfactual analysis focused on easy counterfactuals where a 
redundant tactic is added to a strategy that results in high minority enrollment (Weiner, et. al., 
2012; Ragin, 2008). For example, previous studies have indicated that having a large number of 
enrollment sites is associated with high minority enrollment. Starting with the assumption that 
CCOPs with a large physician cadre and research staff, a large trial menu, and strong policies 
and practices would also be a key tactic resulting in high minority enrollment regardless of the 
number enrollment sites, the truth table can be examined to evaluate if there are logical and 
empirical cases of that strategies that do and do not have membership in the set of CCOPs with a 
large number of enrolling sites. The counterfactual analysis will be unable to produce logically 
simpler strategies resulting in high minority enrollment and “simplifies” the causal conditions for 
that organizational strategy to large physician cadre and research staff, a large trial menu, and 
strong policies and practices. 
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RESULTS 
Descriptive statistics for CCOPs and MBCCOPs are listed in Table 7 and Table 8. 
Enrollment of minority patients in NCI-sponsored treatment trials varied between CCOP and 
MBCCOPs. In the study period, CCOPs enrolled 0-66 minority patients; and MBCCOPs 
enrolled 0-138 minority patients in treatment trials. The 22 logically possible strategies resulting 
in high levels of enrollment of minority patients in clinical treatment trials are described in Table 
9. Our study did not find a single tactic that was necessary for achieving high minority 
enrollment in treatment trials. Our results suggest that a single CCOP strategy consistently 
results in high organizational enrollment of minority patients, whereas MBCCOPs may employ 3 
distinct strategies in order to achieve high organizational enrollment of minorities in trials. 
The CCOP strategy resulting in high organizational enrollment of minorities appears to 
be a variation of the “size matters” theme proposed by Weiner and colleagues (2012). The CCOP 
strategy resulting in high minority enrollment had a large cadre of enrolling physicians, with a 
large staff providing screening and assistance with enrollment at a large number of community 
sites. This CCOP strategy also had supportive policies and practices, with the implementation of 
annual training events; and an expectation that physicians enroll a minimum number of patients, 
and recognition for enrollment of patients in trials. 
The first MBCCOP strategy that consistently results in high minority enrollment simply 
has a large staff that holds at least one annual training event, and physicians enrolling patients in 
treatment trials are not necessarily required to enroll a minimum number of patients. The second 
MBCCOP strategy employs a large research staff that does not provide screening and enrollment 
assistance in a large number of sites; and physicians are not required to enroll a minimum 
number of patients enrolled in treatment trials. The third MBCCOP strategy resulting in high 
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minority enrollment has a small cadre of physicians enrolling patients, with screening and 
assistance for enrollment occurring at a large number of sites. This strategy also includes a large 
menu of available treatment trials and implementation of at least one annual training event, 
however, did not have strong supportive policies or practices. Notably, this strategy also required 
that the MBCCOP does not have the expectation that physicians annually enroll a minimum 
number of patients. 
Consistency scores for each of the strategies were greater than 90% indicating that nearly 
all of the cases with those strategies achieved high enrollment of minorities to treatment trials. 
Counterfactual analysis for the CCOPs did not result in further strategies, or further logical 
reduction of strategies. Coverage scores for overall and individual strategies were low, which is 
not uncommon with high consistency scores (Ragin, 2008). The coverage score for the CCOP 
strategy was 0.16; and the coverage scores for each of the MBCCOP strategies are 0.05, 0.06, 
and 0.01, respectively. Coverage scores indicate the variation in each strategy’s ability to explain 
the outcome of interest. A high coverage score for a strategy indicates that the outcome set is 
highly explained by this particular strategy; however, the low coverage scores in our results 
indicate low empirical relevance for the resulting MBCCOP strategies.  
In order to assess the sensitivity of our analysis, the anchor points for each of tactics 
recommended by NCI officials were increased and decreased by 5%, and two additional fsQCA 
models were run using the revised anchor points to calibrate the study measures. Lowering the 
anchor points resulted in one additional MBCCOP strategy resulting in high minority enrollment. 
This potential MBCCOP strategy had a small cadre of enrolling physicians, and a small research 
staff that does not provide screening and assistance at many enrolling sites. This strategy also 
had a large trial menu, and strong policies and practices to support minority enrollment; but did 
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not meet our inclusiveness criteria of having one empirical case.  Raising the anchor points by 
5% resulted in another CCOP strategy; however it also did not have an empirical case. 
Sensitivity testing appeared to indicate that the fsQCA model was robust to uncertainties in 
substantive knowledge of CCOP and MBCCOP tactics. 
DISCUSSION 
 
This study focused on identifying the strategies and tactics used by CCOPs and 
MBCCOPs in order to achieve high enrollment of minorities in clinical treatment trials. Four 
strategies were identified, including a single strategy for clinical trial organizations that do not 
provide cancer care for large minority populations; and three strategies for organizations serving 
large minority populations. Our study did not find any tactics that are logically necessary for 
high minority enrollment for CCOPs or MBCCOPs. However, it appears that it may be important 
for CCOPs and MBCCOPs to implement annual training events since the CCOP strategy 
achieving high minority enrollment includes an annual training event; and two out of the three 
MBCCOP strategies include an annual training event. Additionally, not implementing an 
expectation for enrollment may also be a key tactic associated with enhanced participation of 
minority patients since the CCOP strategy, and each of the MBCCOP strategies do not include 
an expectation that physicians enroll a minimum number of patients per year. As previously 
mentioned, this may be due to the various types of organizations that comprise a CCOP or 
MBCCOP. For example, large research institutions may be more likely to implement an 
enrollment expectation, and experience greater distrust from minority populations, and therefore 
not achieve high enrollment of minority patients to treatment trials. 
It is not surprising that a CCOP with a substantial amount of resources and strong 
supportive policies is capable of enrolling high numbers of minority patients to treatment trials. 
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This offers support for the claim that enrollment of minorities in clinical trials may require more 
resources to address barriers to participation, but this appears to be the case for organizations that 
do not serve large minority populations. With regards to specific modifiable supportive policies 
and practices, our results indicate that it may important for CCOPs to implement annual training 
events, and an expectation for enrollment among physicians in order to enhance enrollment of 
minority populations; however, CCOPs may not need to implement a system for recognizing 
physician enrollment. Our results provide support for results from a survey of CCOP and 
MBCCOP physicians demonstrating the impact of supportive policies on physician-level 
enrollment in clinical trials (Jacobs, et. al., 2014); but our results did not find that enrollment 
recognition is a key tactic for enhancing enrollment of minorities for CCOPs. This difference 
may be due to predisposed attitudes that CCOP physicians have towards enrollment of patients in 
clinical trials. For example, CCOP physicians receive intrinsic rewards for enrolling patients in 
trials, and small tokens of recognition simply may not have a substantial impact on their attitudes 
towards enrolling minority patients. Additional research focused on tactics that impact CCOP 
physician attitudes towards minority enrollment might be critical in order to enhance minority 
participation in trials at organizations that do not serve large minority populations. 
Our findings support the claim that MBCCOPs implement a variety of strategies in order 
to achieve high levels of minority enrollment in treatment trials (McCaskill-Stevens, et. al., 
2005), and provide support for ongoing NCI policies that promote the development and funding 
of MBCCOPs and other research organizations that serve large minority populations. Our 
findings demonstrate that in order to consistently achieve high levels of minority enrollment, 
MBCCOPs may particularly benefit from having annual training events, or a large research staff.  
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These findings support results of a multivariate analysis of organizational characteristics 
associated with enrollment of blacks to treatment trials that demonstrate a positive net impact of 
implementing an annual training event, or increasing the number of research staff (Belden, et. al., 
dissertation chapter 2). In addition to annual training events as a key CCOP tactic for enrolling 
minorities in treatment trials; two of the MBCCOP strategies resulting in high minority 
enrollment also included training events suggesting that efforts to improve awareness of clinical 
trials is an important aspect of enhancing minority participation in treatment trials for both 
CCOPs and MBCCOPs. Unfortunately, the low empirical relevance of the MBCCOP strategies 
compels us to caution against a strict interpretation that seeking to increase the number of 
research staff or annual training events, for example, will result in greater enrollment of 
minorities in clinical trials. Post-hoc analyses of the empirical cases revealed that having a large 
research staff resulted in high enrollment for a small, academic-based MBCCOP (3 enrolling 
sites), located in a region with nearly a 30% minority population. This strategy appears to differ 
for MBCCOPs in regions with a smaller proportion of minorities (<18%), with two cases 
demonstrating comparable resources; however, achieving high minority enrollment by remaining 
focused on a single enrolling location, or serving 6 enrolling sites. Post-hoc analysis of high 
enrolling CCOP empirical cases suggests that CTOs with substantial resources in regions with 
minority populations ranging from 15-20% are capable of enrolling large numbers of minority 
patients in clinical trials (Table 10). For example, four out of the 6 empirical CCOP strategies 
resulting in high minority enrollment are located in MSAs with less than a 20% minority 
population. Empirically, it appears that the continued funding of CCOPs in regions with minority 
populations of approximately 20% may be an equally effective strategy for enhancing minority 
participation in clinical research as funding “minority-based“ clinical trial organizations. 
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A further examination of cases was conducted in order to identify examples of CCOP and 
MBCCOP strategies resulting in high enrollment of minorities in clinical treatment trials (20+ 
minorities enrolled annually), and are presented in Table 11. The selection of CCOPs and 
MBCCOPs presented in Table 11 is based on the proportion of minorities enrolled annually to 
total enrollment in treatment trials using historical data on enrollment extending back to 2005. 
CCOPs A and B are empirical cases of the “size matters” approach to enrollment, and have large 
numbers of enrolling physicians, large research staff, large trial menu, and supportive policies 
and practices. CCOPs C and D achieved high enrollment of minorities with fewer physicians, 
fewer staff, and small trial menus; but did exhibit strong supportive policies and practices. In the 
fsQCA analysis, these strategies resulted in high minority enrollment, but did not meet the 
threshold for consistency (80%). This suggests that these strategies may result in high enrollment 
of minorities, but do not consistently achieve that outcome. Additional examination of the tactics 
of CCOPs and MBCCOPs may highlight additional strategies that can be employed to enhance 
minority enrollment in treatment trials. The MBCCOP strategies presented in Table 11 illustrate 
the variation in how organizations serving large minority populations enroll high levels of 
minority patients in treatment trials. For example, MBCCOP A has a large number of enrolling 
sites with screening and enrollment assistance, and does not have a large trial menu. MBCCOP B 
has a large research staff, does not have a large trial menu, and is focused on providing screening 
and enrollment assistance at a small number of enrolling locations. MBCCOP C and D have 
large physician cadres, with large trial menus, however MBCCOP C has a large number of 
enrolling sites and a small research staff compared to not many enrolling sites and a large staff 
for MBCCOP D. Future qualitative research is necessary to understand how the tactics identified 
in this study, and other tactics may result in high minority enrollment. 
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A limitation of this study is the possibility that the survey failed to capture tactics with 
the greatest impact on minority enrollment. For example, this study examined the impact of the 
number of research staff at each CCOP or MBCCOP on minority enrollment, but research has 
demonstrated that patient navigators are particularly important in addressing the barriers of 
minority patients (Ghebre, et. al., 2014; Holmes, et. al. 2012; Paskett, et. al., 2011). Further 
research is necessary to examine the impact of patient navigators on minority enrollment at 
institutions that do not serve large minority populations. 
 
 
 
 
 
  
 56 
 
Table 5. Fuzzy-set Anchor Points 
 Full Non-membership 
(CCOP/MBCCOP) 
Crossover 
(CCOP/MBCCOP) 
Full Membership 
(CCOP/MBCCOP) 
Minority enrollment 10/10 16/16 20/20 
No. of enrolling physicians 25/12 51/18 100/25 
No. of research staff 12/4 16/12 25/15 
No. of enrolling sites 4/2 12/4 15/8 
No. of screening sites 4/2 12/4 15/8 
No. of sites with assistance 4/2 12/4 15/8 
No. of available treatment trials 20/10 31/15 50/25 
 
 
Table 6. CCOP Descriptive Statistics 
 Mean SD Minimum Maximum 
Minority enrollment 10 12 0 66 
No. of enrolling physicians 45 36 9 209 
No. of research staff 16 13 2 80 
No. of enrolling sites 14 16 2 87 
No. of screening sites 10 14 0 71 
No. of sites with assistance 11 14 0 69 
No. of available treatment trials 36 16 11 78 
Enrollment expectation 34% - 0 1 
Enrollment recognition 60% - 0 1 
Training Events 36% - 0 1 
 
 
Table 7. MBCCOP Descriptive Statistics 
 Mean SD Minimum Maximum 
Minority enrollment 17 16 0 138 
No. of enrolling physicians 20 13 3 62 
No. of research staff 10 6 3 30 
No. of enrolling sites 5 4 1 16 
No. of screening sites 5 4 1 16 
No. of sites with assistance 5 4 1 16 
No. of available treatment trials 18 10 6 37 
Enrollment expectation 27% - 0 1 
Enrollment recognition 20% - 0 1 
Training Events 53% - 0 1 
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NOTE: M = MBCCOP; P = No. Physicians Enrolling; F = No. Research Staff; S = No. Sites with Screening;  
A = No. Sites with Enrollment Assistance; T = No. Trials Available; X = Enrollment Expectation; E = Training 
Events. 
 
Table 8. Summary Truth Table for Strategies Resulting in High Minority Enrollment 
Strategy 
Solution 
Number of 
CCOPs and 
MBCCOPs  
Consistency 
Value 
Consistency 
Threshold F-test P 
mPFSATXE 2 0.937 0.8 7.69 0.007 
MpfSATxE 1 0.973 0.8 24.48 0 
MpFsatxe 1 0.998 0.8 4353.97 0 
MpFsatxE 0 0.975 0.8 34.6 0 
MpFsaTxe 0 0.982 0.8 59.05 0 
MpFsaTxE 0 0.964 0.8 13.1 0.001 
MpFsAtxe 0 0.954 0.8 7.17 0.01 
MpFsAtxE 0 0.975 0.8 34.6 0 
MpFsATxe 0 0.954 0.8 7.01 0.01 
MpFsATxE 0 0.964 0.8 13.1 0.001 
MpFSatxe 0 0.954 0.8 7.17 0.01 
MpFSatxE 0 0.975 0.8 34.6 0 
MpFSaTxe 0 0.954 0.8 7.01 0.01 
MpFSaTxE 0 0.964 0.8 13.1 0.001 
MpFSAtxe 0 0.954 0.8 7.17 0.01 
MpFSAtxE 0 0.996 0.8 1142.84 0 
MpFSATxe 0 0.954 0.8 7.01 0.01 
MpFSATxE 0 0.996 0.8 981.46 0 
MPFsatxe 0 0.977 0.8 31.87 0 
MPFsatxE 0 0.972 0.8 26.96 0 
MPFsaTxe 0 0.976 0.8 31.54 0 
MPFsaTxE 0 0.964 0.8 13.1 0.001 
MPFsAtxe 0 0.954 0.8 7.17 0.01 
MPFsAtxE 0 0.972 0.8 26.96 0 
MPFsATxe 0 0.954 0.8 7.01 0.01 
MPFsATxE 0 0.964 0.8 13.1 0.001 
MPFSatxe 0 0.954 0.8 7.17 0.01 
MPFSatxE 0 0.972 0.8 26.96 0 
MPFSaTxe 0 0.954 0.8 7.01 0.01 
MPFSaTxE 0 0.964 0.8 13.1 0.001 
MPFSAtxe 0 0.954 0.8 7.17 0.01 
MPFSAtxE 0 0.996 0.8 1089.68 0 
MPFSATxe 0 0.954 0.8 7.01 0.01 
MPFSATxE 0 0.996 0.8 981.46 0 
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Table 9. Simplified Strategies for Achieving High Minority Enrollment 
 Strategy 
Tactics 1 2 3 4 
MBCCOP  X X X 
Many Physicians Enrolling X x   
Large Research Staff X  X  
Many Screening Sites X X x  
Many Sites with Enrollment Assistance X X x  
Many Trials Available X    
Enrollment Expectation X x x x 
Enrollment Recognition X    
Annual Training Event X X  X 
 
NOTE: Upper-case X indicates causal condition (tactic) present; lower-case x indicates causal condition absent. 
Abbreviation: MBCCOP, Minority-based Community Clinical Oncology organization. 
 
 
Table 10. Empirical Strategies for Achieving High Minority Enrollment 
 Empirical Strategy 
Tactics 1 2 3 4 5 6 7 8 9 
MBCCOP x x x x x x X X X 
Many Physicians 
Enrolling 
x X x X X x x x x 
Large Research Staff x x X X X x X x x 
Many Screening Sites x x x X X x x x x 
Many Sites with 
Enrollment Assistance 
x x x X X x x x x 
Many Trials Available x x X X X X x x x 
Enrollment Expectation x X X X X X x x x 
Enrollment Recognition x x X X X x X x x 
Annual Training Event x x X X X X x X X 
MSA Proportion 
Minority Population 
33% 17% 20% 25% 15% 16% 29% 16% 17% 
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TABLE 11. Detailed Organizational Characteristics of CCOP/MBCCOPs Achieving High Minority Enrollment in Treatment 
Trials 
 MBCCOP 
A 
MBCCOP  
B 
MBCCOP 
C 
MBCCOP 
D 
CCOP 
A 
CCOP 
B 
CCOP 
C 
CCOP 
D 
Funded 2007 2001 1994 1990 1994 1988 1983 1983 
1. Organizational 
Structure 
Research 
institute, 
department, 
or center 
Separate, 
non-profit 
organization 
Hospital 
Cancer 
Center 
Hospital 
Cancer 
Center 
Hospital 
Cancer 
Center 
Separate, 
non-profit 
organization 
Hospital 
Cancer 
Center 
Research 
institute, 
department, 
or center 
2. Enrollment 
Minimum 
No No No No Yes Yes Yes No 
3. Feedback on 
Personal  
Enrollment 
No No Monthly, 
Quarterly 
Monthly Annual Quarterly No Monthly 
4. Feedback on 
CCOP Enrollment 
Monthly Monthly Monthly, 
Quarterly 
Monthly Quarterly Quarterly Monthly Monthly 
5. Recognition for 
Enrolling 
Physicians 
No No No No Yes Yes No No 
6. Education and 
Training Events 
1 1 0 0 1 1 0 0 
7. Disparities 
Education and 
Training Events 
1 0 0 0 0 0 0 0 
8. CCOP PI Input 
for Opening 
Clinical Trials 
Yes Yes No Yes Yes Yes Yes Yes 
9. No. Physicians 
Enrolling  
11 13 47 30 100 193 66 28 
10. No. Physicians 
for whom Charts 
are Screened 
10 13 21 30 100 155 25 14 
11. No of 
Physicians who 
Receive Routine 
Assistance with 
Enrollment 
10 10 13 30 100 161 25 14 
12. No. of 
Enrolling Sites 
6 1 9 3 56 87 40 4 
13. Sites Where 
Patient Charts are 
Screened 
4 1 6 3 56 71 7 4 
14. Sites Where 
Staff Assist with 
Enrollment 
4 1 6 3 56 69 7 4 
15. CCOP Staff 
Members 
5 10 5 30 42 78 8 11 
16. No. CCOP 
Registered Nurses 
0 0 3 10 26 42 6 5 
17. No. Non-Nurse 
Clinical Research 
Associates 
4 7 1 9 16 28 1 5 
18. No. Staff 
Members Focused 
on Control Trials 
1 1 0 4 3 14 8 1 
19. No. Regulatory 
Staff Members 
1 2 2 4 3 16 1 1 
20. No. of 
Available 
Treatment Trials  
10 6 29 23 61 70 24 28 
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CHAPTER 4: GEOGRAPHIC ACCESS TO CLINICAL TRIAL ORGANIZATIONS IN 
THE US 
 
INTRODUCTION 
 
Twenty years since the NIH mandated the inclusion of minorities in NIH funded research, 
minorities remain disproportionately affected by cancer, and continue to experience substantial 
barriers to participating in cancer clinical trials when compared with non-Hispanic whites (Chen, 
et. al., 2014; Durant, et. al., 2014; Newman, et. al., 2008; Stewart, et. al., 2007; Murthy, et. al., 
2004; Sateren, et. al., 2002). Systematic reviews of minority participation in clinical research 
reveal extensive research on patient-level barriers to participation in clinical trials, and research 
has demonstrated that travel time is a key barrier to minority participation in clinical trials 
(Durant, et. al., 2014; Holmes JA, et. al., 2012; Ford et. al., 2008; UyBico, et. al., 2007). 
Improving minority participation in clinical trials suggests the need for clinical trial 
organizations that are located in close proximity to areas with sizable minority populations 
(Joseph and Dohan, 2009); however, the associations between travel time to clinical trial 
organizations (CTOs) and detailed population demographic characteristics (e.g. race/ethnicity, 
race/ethnicity by urban versus rural areas, and race/ethnicity by region) are currently unknown.  
Previous studies have examined geographic disparities in access to specialized cancer 
care using estimated travel times from Zip Code Tabulation Areas (ZCTAs) to NCI Cancer 
Centers, academic medical centers, and community-based oncology specialists (Onega, et. al., 
2008; Onega, et. al., 2009; Onega, et. al., 2010). These studies specifically examined place 
accessibility, a measure of spatial separation, versus individual accessibility, which measures 
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variation in geographic access based on individual characteristics (Shi, et. al., 2012; Kwan, 1998). 
Results suggested that 69.4% of the US population has less than one hour of travel time to an 
academic-based cancer care organization, and found the overall median travel time to academic-
based cancer care was 30 minutes (Interquartile range, 13-72). In addition to a wide range of 
travel times, the study also found wide variation by race, regions, and demographic 
characteristics. Overall, results suggested that rural areas experience substantial disparities in 
geographic access to CTOs. Black populations had shorter median travel time than whites or 
Hispanics in urban ZCTAs, but blacks in rural areas experienced greater travel times. The study 
also found disparities in geographic access to specialized cancer care organizations for Native 
Americans, and other minority populations residing in rural ZCTAs. Additional research by 
Onega and colleagues (2010) found that whereas African Americans in urban settings have 
comparable travel times to cancer care organizations as Caucasians, rural African Americans 
experience significant disparities in travel time to NCI Cancer Centers, particularly in the South. 
The majority of specialized cancer care in the US is provided in a community-based setting, and 
a key limitation of Onega and colleague’s analyses was the failure to capture the locations of 
CCOPs and MBCCOPs, and other organizations offering NCI-sponsored treatment trials, which 
may lead to erroneous conclusions regarding disparities in geographic access to organizations 
offering NCI-sponsored clinical trials. Therefore a detailed examination of disparities in 
geographic access to clinical trial organizations is necessary to address disparities in minority 
participation in clinical research. 
This study employed the network geographic analysis approach employed by Onega and 
colleagues (2008) with data on organizations participating in the NCI Community Clinical 
Oncology Program and the American College of Surgeons Commission on Cancer approved 
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cancer centers in order to estimate median travel times from ZCTAs to the nearest location 
offering NCI-sponsored clinical treatment trials, and investigate disparities in geographic access 
to clinical trial organizations (CTOs) for racial and ethnic groups in the continental US. To our 
knowledge, this is the first study to estimate travel times to organizations offering NCI-
sponsored clinical trials for demographic groups in the US. 
CLINICAL TRIAL ORGANIZATIONS 
 
NCI Community Clinical Oncology Program (CCOPs and MBCCOPs) 
 
Since 1983, the NCI Community Clinical Oncology Program has implemented over 60 
networks of clinical trial organizations in community-based settings across the US (Minasian, et. 
al., 2010). The Community Clinical Oncology Program is comprised of: (1) NCI’s Division of 
Cancer Prevention providing overall direction and funding, (2) Clinical Research Group Bases 
and NCI Cancer Centers providing design and development of clinical trials, and (3) the clinical 
trials organizations enrolling patients. The clinical organizations,’ hereafter referred to as 
“CCOPs” or “MBCCOPs” for CCOPs which specialize in providing cancer care to minority 
populations, are collaborations between physicians and oncology physicians in academic medical 
centers, community-based hospitals and private practices. In 2014, 47 CCOPs represent more 
than 300 hospitals, and more than 3,000 physicians. Additionally, a total of 17 MBCCOPs 
represent 55 hospitals and approximately 500 physicians. The primary goals of CCOPs and 
MBCCOPs are engaging physicians in clinical research, disseminating clinical research findings 
into community practice, and enrolling patients in NCI-sponsored clinical trials. CTOs 
participating Community Clinical Oncology Program have been very successful, resulting in 
one-fifth of minority patients enrolled in NCI-sponsored clinical treatment trials (Minasian, et. 
al., 2010). We included all active hospitals and enrolling sites affiliated with the Community 
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Clinical Oncology Program located in the continental US in this analysis. We excluded CCOPs 
and MBCCOPs in Alaska, Hawaii, and Puerto Rico due to the different commuting patterns in 
those states per Onega and colleagues (2008). 
Commission on Cancer Accredited Hospitals (CoC) 
 
 Over 70% of newly diagnosed cancer patients are treated annually at more than 1500 
Commission on Cancer accredited hospitals in the US. The American College of Surgeons 
Commission on Cancer grants different categories of accreditation to hospitals in the US. These 
include Comprehensive Community Cancer Programs, Community Cancer Programs, Academic 
Comprehensive Cancer Programs, Integrated Network Cancer Programs, Hospital Associate 
Cancer Programs, Free Standing Cancer Center Programs, and NCI-designated Comprehensive 
Cancer Centers (NCI Cancer Centers). Hospitals categorized as Comprehensive Community 
Cancer Programs provide services to 500 or more newly diagnosed cancer patients and offer a 
range of cancer care services, and enroll or refer patients to clinical trials. Hospitals categorized 
as Community Cancer Programs annually serve between 100 and 500 newly diagnosed cancer 
patients with diagnostic and treatment services, and directly enroll or refer patients to clinical 
trials. Hospitals categorized as Academic Comprehensive Cancer Programs provide medical 
education, diagnostics and treatment, and enroll or refer patients to clinical trials. Integrated 
Network Cancer Programs do not have minimum cancer caseloads, but either directly enroll 
patients to clinical trials, or refer patients to clinical trials at other organizations. Hospital 
Associate Cancer Programs serve 100 or fewer newly diagnosed cancer patients annually, 
provide a limited range of cancer care services, and have the option to participate in offering or 
referring patients to clinical trials. The Free Standing Cancer Center Program includes 
organizations that are not hospitals, but provide a range of diagnostic and treatment services, 
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with on-site clinical trials and referrals to other organizations offering clinical trials. NCI-
designated Comprehensive Cancer Centers receive peer-reviewed funding, offer a full range of 
diagnostic and treatment services, and directly enroll patients in clinical trials.  
METHODS 
Data Sources 
Data for this study were obtained from: the US Census, American Community Survey, 
The US Department of Agriculture Economic Research Service, the American College of 
Surgeons, the National Cancer Institute website, and NCI Community Clinical Oncology 
Program Progress Reports. ZCTA shapefiles and geographic data for 2010 were obtained from 
the US Census. American Community Survey 2008-2012 5-year estimates of racial and ethnic 
population totals were abstracted and matched to the ZCTAs. Rural Urban Commuting Area 
Codes data were used to determine the status of each ZCTA as follows: Urban, Suburban, Small 
Rural Town, Rural and isolated areas. In this analysis, we included all NCI-designated 
Comprehensive Cancer Centers, and all other CoC organizations with research nurses. Finally, 
hospitals participating in the Community Clinical Oncology Program were identified from 
Annual NCI Progress Reports and included in the analysis if operating in 2012.  
Data Analysis 
Geographic locations for NCI-designated Cancer Centers, hospitals and physician 
practices participating in the NCI Community Clinical Oncology Program, and Commission on 
Cancer hospitals in the continental US were converted to latitude/longitude and mapped using 
BusinessMAP 4.0 software (Environmental Systems Research Institute). These locations were 
then individually assessed using Google Maps for accuracy. Longitudes and latitudes of 
population centroids for each zip code tabulation area (ZCTA) were mapped in ArcGIS 10.1 
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software (Environmental Systems Research Institute) and matched to the demographic 
characteristics data from the American Community Survey. Per Onega and colleagues (2008), 
travel times were estimated in ArcView GIS Network Analyst using the closest facility algorithm 
that establishes unique origin-destination pairs and evaluates the one-way travel time between 
the origin and the destination (ESRI). This study estimated travel time from each ZCTA in the 
continental United States to the nearest clinical trial organization based on a major and minor 
road network that accounted for travel burden with speed limits assigned to road segments. 
Briefly, this method classified roads into segments and assigned each segment an average travel 
speed adjusted for rural versus urban status. Per Onega and colleague’s study (2008), travel times 
were calculated for each region with a 250-mile road network buffer. A 250-mile road network 
buffer is used to estimate ZCTAs with more than four hours of travel time to the nearest CTO. A 
4-hour travel time was selected as the threshold at which attendance at a CTO is achievable in 1 
day of travel (Onega et. al., 2008). Travel time categories were analyzed at: <30 minutes, 30 
minutes to <1 hour, 1 hour to <2 hours, 2 hours to <3 hours, 3 hours to <4 hours, and greater 
than 4 hours. In order to evaluate demographic characteristics of the US population proximate to 
CTOs, ACS data was matched to each ZCTA. Finally, Rural-Urban Classification Area data 
(3.0) was matched to ZCTAs to evaluate urban versus rural travel times to CTOs. 
RESULTS 
 
The analysis included 32,961 ZIP codes in the continental US, and a total population of 
307,049,317. Our analysis found 429 ZIP codes contained a CCOP or MBCCOP (n = 497, 1.3%). 
American College of Surgeons Commission on Cancer accredited hospitals are located in 1199 
ZIP codes (n =12833, 4.0%). A total of 1509 ZIP codes contained at least one CCOP, MBCCOP, 
or CoC organization (4.6%). For the total population, geographic access to CTOs appears to be 
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excellent, and there are few ZCTAs in the continental US where geographic access to any CTO 
is poor. Overall, results suggest that nearly 95% of the US population resides within one hour of 
any CTO. Moreover, our analysis did not find a ZCTA centroid more than 4 hours away from 
any CTO, and less than 1% of the total US population was located more than 3 or more hours 
from any CTO (Table 11). Median travel times to CTOs for all races and ethnic groups in the 
study are presented in Table 12. The median travel time to any CTO for the total population is 28 
minutes (IQR = 11-40 minutes), 28 minutes for white populations (IQR = 13-41 minutes), 28 
minutes for African American population (IQR = 16-37 minutes), 30 minutes for Hispanic 
populations (IQR = 16-34 minutes), 26 minutes for Asian populations (14-36 minutes), and 27 
minutes for Native American population (IQR = 16-30 minutes).  
Median travel times by race and RUCA codes are presented in Table 13. Urban 
populations in the US experience the lowest travel times to any CTO (20.8 minutes), with 
increasing travel times for suburban populations (34.0 minutes), populations in small rural towns 
(38.2 minutes), and populations in isolated rural areas (38.8 minutes).  Travel times to any CTO 
for white populations mirror the travel times for the total population in urban (20.8 minutes), 
suburban (34.0 minutes), rural towns (38.2 minutes), and isolated or rural regions (38.8 minutes). 
Urban black populations experience greater travel times to any CTO than the total population 
(23.0 minutes), and similar travel times in suburban regions (33.6 minutes); however, black 
populations experience lower travel times to any CTO than the total population in rural towns 
(33.9 minutes) and isolated rural areas (36.6 minutes). Hispanic populations experience the 
greatest travel time to any CTO in urban areas (25.3 minutes). However, Hispanic populations 
experience similar travel times as the total population in suburban areas (33.5 minutes), and 
lower travel times than the total population to any CTO in rural towns (33.6 minutes) and 
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isolated rural areas (33.6 minutes). Asian populations experience greater travel time to any CTO 
than the total population in urban areas (24.0 minutes) and suburban areas (35.5 minutes), 
however, they experience lower travel times in rural towns (35.5 minutes) and isolated rural 
areas (35.5 minutes). Native American populations experience greater travel times to any CTO 
than the total population in urban areas (24.0 minutes); but travel times for Native American 
populations are lower than the total population in suburban (30.1 minutes), rural towns (30.1 
minutes), and isolated rural areas (30.1 minutes). 
 Travel times to any CTO by race and region are presented in Table 14. Travel time for 
the total population to any CTO is lowest in the Northeast region (22.8 minutes). The median 
travel time for the total population to any CTO is greater in the South (27.1 minutes), West (29.0 
minutes), and Midwest (29.3 minutes). Travel times for white populations mirror the total 
population in the Northeast region (22.8 minutes), South region (27.1 minutes), West region 
(29.0 minutes), and Midwest region (29.3 minutes). Black populations experience greater travel 
time than the total population in the Northeast region (26.7 minutes) and Midwest region (31.3 
minutes), similar travel time to the total population in the West region (28.8 minutes); however 
travel times to any CTO for Black populations are lower in the South than the total population 
(23.1 minutes). Hispanic populations experience the greatest travel times in the Northeast region 
(29.5 minutes). However, Hispanic populations experience similar travel times as the total 
population in the South region (27.5 minutes), lower travel times in the West region (25.7 
minutes), and greater travel times in the Midwest region (31.6 minutes). Asian populations 
experience greater travel times than the total population in the Northeast region (27.3 minutes), 
South region (29.2 minutes), and Midwest region (33.2 minutes); however, Asian populations 
experience lower travel times than the total population in the West (25.8 minutes). Native 
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American populations experience greater travel times to any CTO than the total population in the 
Northeast (29.3 minutes), lower travel times in the South region (24.5 minutes) and West region 
(21.6 minutes), and similar travel times to the total population in the Midwest (30.0 minutes). 
DISCUSSION 
The goal of this study was to examine disparities in geographic access to CTOs offering 
NCI-sponsored clinical trials for racial/ethnic groups in the continental US. There is currently no 
standard for travel time to a CTO; however, Congress has set a goal that US populations should 
live within 200 miles of an NCI Cancer Center (NCI Cancer Bulletin, 2002). Onega and 
colleagues’ study (2008) demonstrated that geographic access to NCI Cancer Centers is adequate 
for most racial/ethnic populations in the US, and this study demonstrates that overall geographic 
access to CTOs is excellent for racial/ethnic groups in the US. The median travel time from 
ZCTA centroids to any CTO for the total US population was 28 minutes, ranging from 11-40 
minutes. This compares favorably to Onega and colleagues (2008) study, which found the 
median travel time from ZCTA centroids to any academic-based cancer care organization was 30 
minutes, ranging from 13-72 minutes.  
With regards to overall racial/ethnic disparities in geographic access to organizations 
offering NCI-sponsored treatment trials, this study demonstrates that most ethnic/racial 
populations in the US reside within 30 minutes or less to the nearest CTO. Overall, our study 
demonstrates that African American populations in the US experience a similar median travel 
time to any CTO as the total population (28 minutes). These results differ from Onega and 
colleagues’ study (2008), which demonstrated that the median travel time for all populations to 
an academic-based cancer care organization is 30 minutes, whereas the median travel time for 
African Americans to an academic-based cancer care organization is 15 minutes. It is unclear 
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whether this difference is due to the proximity of academic medical centers to inner city 
populations as proposed in previous studies (Kahn, et. al., 1994); or findings from Onega and 
colleagues’ study (2010) that a greater proportion of African Americans than Whites live within 
30 minutes of academic medical centers (66% vs. 45%). However, data on academic medical 
centers offering clinical treatment trials were unavailable, and future studies examining 
geographic access to CTOs using locations of academic medical centers may reveal that African 
Americans have lower travel times to CTOs than the total population. This study demonstrates 
that Hispanic populations in the US generally experience the greatest travel time to any CTO. 
These results differ from Onega and colleague’s (2008) study that suggested Native Americans 
experience the most substantial disparities in geographic access to cancer care organizations; 
however, this may be due to the lack of CTOs in the Southwestern region of the US, and the 
extensive reach of CCOP and MBCCOP sites in remote regions in the Midwest where Native 
American populations are concentrated. Our results suggest that policies are needed to address 
disparities in geographic access to CTOs for Hispanic populations, particularly in the Southwest 
regions of the US where Hispanic populations are concentrated, and there are few CTOs. Our 
analysis supports previous results from Onega and colleagues’ study demonstrating that Asian 
populations experience the least disparities in geographic access, which is likely due to the 
concentration of Asian populations residing in urban areas (Onega, et. al., 2008). 
Onega and colleagues (2008) study demonstrated the importance of urban versus rural 
place of residence and disparities in geographic access to specialized cancer care organizations. 
For example, their study found the median travel time to an academic-based care organization 
for populations dwelling in isolated rural areas was 105 minutes, with an interquartile range from 
76-153 minutes. Previous research has demonstrated disparities in geographic access to clinical 
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trials for urban and rural populations (Baquet, et. al., 2006). However, our study has 
demonstrated that the efforts of the Community Clinical Oncology Program and the ASCO 
Commission on Cancer to extend clinical research into community-based settings appears to 
ameliorate rural versus urban disparities in access to CTOs when compared to geographic access 
to academic-based cancer care organizations. For example, our study found that all racial/ethnic 
groups in rural regions appear to reside within a maximum of 50 minutes to a CTO. 
Unfortunately, whereas our results demonstrate that disparities in place accessibility for rural 
populations may be less than previously considered, disparities in individual accessibility may be 
the key factors limiting geographic access to clinical treatment trials for rural dwelling 
populations. 
This study identifies specific regions with disparities in geographic access to CTOs for 
racial/ethnic groups in the continental US. Our results provide mixed support for Onega and 
colleagues (2008) contention that disparities in geographic access to cancer care organizations 
are most prominent in the South. Their analysis included the NCI Cancer Center located at the 
University of Alabama at Birmingham, but failed to include the locations of CTOs participating 
in the Southeast Cancer Control Consortium CCOP, the Upstate Carolina CCOP, Greenville 
CCOP, Atlanta Regional CCOP, Georgia Regents MBCCOP, and the Virginia Commonwealth 
University MBCCOP. Post-hoc analysis examining point locations of CCOPs, MBCCOPs, and 
CoC hospitals in the South clearly show a substantial number of CTOs in North Carolina, South 
Carolina, Georgia, and Louisiana, and the overall lack of cancer care organizations in Alabama 
and Mississippi. Moreover, examination of all CTOs with 50-mile buffers in the US further 
highlights small regions with disparities in geographic access in Alabama and Mississippi 
(Figure 4). These particular areas may be in the greatest need of enhanced, and tailored 
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organizational efforts to make trials more geographically accessible to all racial and ethnic 
populations that dwell in the Black Belt and Mississippi Delta regions of the US. 
A limitation in using the network geographic methods proposed by Onega and colleagues 
(2008) is that origin-destination pairs do not always match up perfectly to road networks, which 
could potentially lead to inaccurate local travel burden and travel times. In those cases (<2%), we 
used estimates of travel time from Google Maps API. Additionally, there can be substantial 
variation in different approaches to estimating travel times; and previous research has suggested 
that predicted travel times might be longer than observed travel times for urban and suburban 
ZIP codes, and shorter for rural ZIP codes (Bliss, et. al., 2012). However, models evaluating 
distance between ZCTA centroids and hospitals have been found to be adequate in accurately 
measuring geographic access (Bliss, et. al., 2012). The strength of this study is that it highlights 
an approach that can be used in order to examine disparities in geographic access to 
organizations that provide high-quality, or perhaps even NCI-quality cancer care. Further 
Research by Onega and colleagues (2010) has demonstrated that African Americans and 
Caucasians who seek cancer care at National Cancer Institute (NCI) Cancer Centers have no 
differences in adjusted 1-year mortalities, 3-year all-cause mortalities, and cancer-specific 
mortalities (Onega, et. al., 2010b). Moreover, previous studies have shown that travel time is a 
significant predictor of attendance at NCI Cancer Centers; and suggested that wide variations in 
travel time by race and place of residence contribute to disparities in access and utilization of the 
most specialized cancer care (Onega, et. al., 2010; Onega, et. al., 2009a; Onega, et. al., 2008). 
Future studies on disparities in geographic access to high-quality cancer care should consider a 
network geographic approach using locations of organizations providing high-quality cancer care. 
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In 2014, the Community Clinical Oncology Program was reorganized into the newly 
funded NCI Community Research Program (NCORP); however, the goals of offering clinical 
trials in community settings and reducing disparities remain the same. Unfortunately, the 
reorganization resulted in the overall reduction of NCI-sponsored CTOs, particularly in the 
South and Southwestern regions of the US. As previously noted, these regions already 
experience disparities in geographic access to CTOs, and a reduction in CTOs may exacerbate 
existing disparities in geographic access to CTOs in the South and Southwest for all racial/ethnic 
populations residing in those regions. A post-hoc analysis of travel times to the nearest CTOs 
that excluded MBCCOP enrolling sites demonstrates the impact of MBCCOPs on travel times 
for racial/ethnic groups in the continental US. MBCCOPs appear to reduce travel times to the 
nearest CTO for all racial/ethnic groups, and removal of the MBCCOP sites resulted in increased 
travel times for all racial/ethnic groups in urban, suburban, large towns, and isolated rural areas. 
Increasing rurality yielded proportionally larger increases in travel times for each racial/ethnic 
group. In this analysis, Hispanic populations are projected to experience the greatest increases in 
travel times without MBCCOP enrolling locations. However, the increase in median travel times 
across urban and rural geographies did not exceed ten minutes; and increases in interquartile 
ranges did not exceed 15 minutes for any racial/ethnic group.  
Results are similar with regards to the impact of excluding MBCCOP enrolling sites on 
travel times to CTOs for racial/ethnic groups by region. Median travel times increase for ZCTAs 
in the Northeast, South, West, and Midwest for all racial/ethnic groups, particularly Hispanic 
populations. However, increases in travel times do not exceed 8 minutes, and interquartile range 
increases do not exceed 10 minutes. In light of the recent restructuring of NCI’s clinical trials 
infrastructure, additional analyses using geocoded data on recent grantees of NCORP are crucial 
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in order to ensure that there is no disruption in the previous efforts of NCI’s to ameliorate 
disparities in access to clinical treatment trials. Moreover, additional research focused on 
investigating disparities in geographic access in small-area regions in the South and Southwest 
may be more productive for health care systems and regional authorities to improve 
dissemination of results from cancer research to community-based settings where minority 
populations seek care. 
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Figure 3: Travel Times to Clinical Trial Organization from ZCTAs for Racial/Ethnic Groups 
< 30 min   30 min. to 1 hr.  1 hr. to 2 hrs.  2 hrs. to 3 hrs.  3 hrs. to 4 hrs. 
Total 
Population 
White Population 
African American Population  Hispanic Population 
Asian Population American Indian Population 
 75 
 
Table 12. Proportion of US Population Across Categories of Travel Time to Nearest CT     
                    Organization 
 
Travel times to clinical trial organization 
 
% Population (n=307,049,317) 
 
<30 30-60   1-2   2-3     3-4      >4 
mins mins hours hours hours hours 
CCOP/MBCCOP Hospitals         43.8 15.3 21.8 10.6 4.8 3.8 
Commission on Cancer Hospitals*        82.4 10.5    5.1          1.7 0.3 0.0 
All Clinical Trial Orgs          84.0 10.3    4.6    0.9 0.2 0.0 
 
* Commission on Cancer hospitals includes CCOPs and MBCCOPs that are also categorized as CoC 
hospitals. 
 
 
Table 13. Median Travel Times to Clinical Trial Organizations for the US Population in the  
                    Continental US    
Population in CCOP/  CoC 
Millions (%) MBCCOP (IQR) Hospital (IQR) Any CTO (IQR) 
Total Population* 307.04 (100) 71 (43-100) 31 (13-45) 28 (11-40) 
White   235.20 (76) 72 (44-99) 30 (15-45) 28 (13-41) 
African American 41.86 (14) 72 (56-82) 30 (17-40) 28 (16-37) 
Hispanic  50.37 (16) 70 (55-83) 33 (17-36) 30 (16-34) 
Asian   16.45 (5) 74 (57-81) 34 (14-39) 26 (14-36) 
Native American  4.88 (2)  67 (56-76) 31 (17-32) 27 (16-30) 
Urban core  263.01 (85) 50 (50-88) 16 (16-51) 16 (16-51) 
Suburban areas  28.05 (9) 50 (50-87) 24 (24-37) 22 (22-32) 
Large town areas 9.15 (4)  62 (62-84) 23 (23-51) 21 (21-47) 
Isolated/rural areas 6.81 (2)  78 (58-78) 29 (19-55) 29 (19-55) 
Northeast  54.89 (18) 63 (63-71) 29 (14-29) 26 (14-26) 
Midwest  71.17 (23) 84 (38-84) 23 (23-29) 23 (23-24) 
South   110 (36) 62 (62-71) 25 (25-26) 23 (23-25) 
West   69.67 (23) 60 (60-84) 25 (25-31) 23 (23-29) 
 
* Total population in racial/ethnic categories exceeds 100% because “Hispanic” is not an exclusive 
category. Commission on Cancer hospitals includes CCOPs and MBCCOPs that are also categorized as 
CoC hospitals. Any CTO includes NCI Cancer Centers, CCOPs/MBCCOPs, Academic Medical Centers, 
and CoC Hospitals. 
Table 14. Median Travel Times (IQR) to Any CTO for Racial/Ethnic Groups and RUCA Codes 
 
   Urban  Suburban Large Town Rural/Isolated 
 
Total Population  21 (9-35) 34 (24-46) 38 (29-49) 39 (30-49) 
White   21 (9-35) 34 (24-46) 39 (29-50) 39 (30-49) 
Black   23 (11-34) 27 (20-34) 27 (22-34) 30 (25-35) 
Hispanic  25 (11-34) 34 (27-34) 34 (28-34) 34 (30-34) 
Asian   24 (9-36) 27 (18-32) 28 (22-32) 32 (28-34) 
Native American  24 (13-30) 26 (18-31) 26 (18-31) 30 (24-34) 
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Table 16. Median Travel Times (IQR) to Any CTO for Racial/Ethnic Groups and Regions 
 
   Northeast South  West  Midwest 
 
Total Population  23 (9-36) 27 (14-41) 29 (11-44) 29 (17-41) 
White   23 (9-36)  27 (14-41) 29 (11-44) 29 (17-41) 
Black   22 (11-29) 23 (10-28) 21 (10-29) 26 (15-32) 
Hispanic  30 (14-34) 27 (14-34) 25 (10-34) 32 (23-34) 
Asian   16 (7-28) 18 (9-28) 13 (6-26) 25 (12-32) 
Native American  24 (15-30) 20 (11-27) 16 (9-27) 30 (16-31) 
 
 
 Table 17. Median Travel Times (IQR) to Any CTO for Racial/Ethnic Groups and Regions 
WITHOUT MBCCOP enrolling locations 
 
   Northeast South  West  Midwest 
 
Total Population  29 (11-45) 34 (16-50) 36 (13-54) 37 (21-51) 
White   29 (11-45)  34 (17-50) 37 (13-55) 36 (21-51) 
Black   27 (14-36) 25 (13-35) 26 (12-35) 32 (19-39) 
Hispanic  36 (18-42) 27 (14-34) 32 (12-42) 39 (29-42) 
Asian   20 (8-35) 23 (11-35) 16 (8-33) 31 (15-40) 
Native American  30 (19-37) 25 (14-34) 21 (11-34) 31 (19-38) 
 
 
 
Table 15. Median Travel Times (IQR) to Any CTO for Racial/Ethnic Groups and RUCA Codes 
Without MBCCOP Enrolling Locations 
 
   Urban  Suburban Large Town Rural/Isolated 
 
Total Population  25 (10-43) 43 (30-57) 48 (36-62) 49 (38-62) 
White   25 (10-43) 43 (30-57) 48 (36-62) 49 (38-62) 
Black   24 (11-34) 34 (25-41) 33 (27-40) 37 (31-42) 
Hispanic  31 (13-42) 42 (34-42) 42 (34-42) 42 (37-42) 
Asian   24 (10-37) 33 (23-40) 34 (27-40) 39 (34-41) 
Native American  24 (13-34) 33 (22-39) 32 (23-39) 37 (29-41) 
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Figure 4. CTOs in the Continental US with 50-mile Buffers 
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CHAPTER 5: SUMMARY OF FINDINGS AND IMPLICATIONS FOR POLICY, 
PRACTICE AND RESEARCH 
 
 The National Cancer Institute is currently undergoing a reorganization of its 
organizational infrastructure. In 2014, the Community Clinical Oncology Program and the 
Community Cancer Centers program were integrated into the newly funded NCI Community 
Oncology Research Program (NCORP). The goal of this dissertation was to investigate 
organizational determinants of minority participation in clinical treatment trials, and findings 
from the three studies have implications on policy, practice, and research. Results from the 
multivariate regression analysis in Aim 1 demonstrate that cancer care organizations that serve 
large minority populations are critical components of the overall strategy of the NCI to reduce 
disparities in cancer care, and enroll minority populations in clinical treatment trials. Holding 
other factors fixed, organizations that serve large black populations will enroll an average of 13 
blacks to clinical treatment trials (p < 0.05). To put this in context, NCI Division of Cancer 
Prevention officials established that a CCOP or MBCCOP that enrolls twenty minority patients 
in treatment trials has achieved high enrollment of minorities. Therefore, research organizations 
that serve large minority populations have the potential to enroll nearly two-thirds of that 
performance goal, regardless of other organizational characteristics that may promote enrollment 
in treatment trials. 
Aim 1 was the first study to empirically examine the impact of the organizational 
structure of CCOPs and MBCCOPs on enrollment of blacks to clinical treatment trials. Whereas 
previous studies of overall enrollment of patients to clinical trials by CCOPs found mixed results 
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regarding the impact of the number enrolling physicians, available treatment trials, and enrolling 
sites (Carpenter, et. al., 2012; Carpenter, et. al., 2006), these studies did not include a measure of 
the number of research staff. Our analysis in Aim 1 included data on the number of research staff, 
and found by adding that key resource as a variable, the impacts of physicians, trials, and staff 
were reduced from previous estimates. This finding suggests that previous analyses examining 
overall enrollment in treatment trials need to be replicated with the inclusion of measures of 
research staff to enhance our understanding of their impact on overall treatment trial enrollment. 
Aim 1 also included three additional novel measures of PBRN supportive policies and practices, 
and found that implementing an enrollment expectation may result in reduced enrollment of 
blacks in treatment trials (p < 0.05). Conversely, recognition for enrollment (p < 0.10) and 
annual training events (p < 0.05) are associated with positive and moderate impacts on black 
enrollment. Finally, Aim 1 also found that managed care penetration has a large and significant 
impact (p < 0.01); a state mandate to cover clinical trials has a moderate and significant impact 
(p < 0.05); and local hospital competition does not appear to be competition at all with a small, 
yet positive, impact on black enrollment in treatment trials. These findings indicate that whereas 
organizational characteristics may inhibit or promote enrollment of minorities in treatment trials, 
environmental characteristics of CCOPs and MBCCOPs are still important factors associated 
with minority enrollment.  
 The results from Aim 1 have implications for policy, practice, and research. First, it 
appears that continued funding of clinical trial organizations dedicated to serving minority 
populations may make logical sense. Moreover, based on the impact of “hospital competition,” 
NCI officials should consider funding both a CCOP and an MBCCOP in regions where minority 
populations are concentrated. With regards to practice, it is unfortunate that only three 
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modifiable organizational characteristics (training events, enrollment recognition, research staff) 
appear to have a significant impact on black patient enrollment. CCOPs and MBCCOPs should 
consider organizing annual training events and implementing efforts to recognize physicians for 
enrolling patients in treatment trials if they are not already doing so. Additionally, MBCCOPs, in 
particular, need to carefully consider whether a requirement on physicians to enroll patients in 
treatment trials is necessary and desirable. In practice, it appears that the number of physicians 
may be less important than the size of the research staff for enrollment of minorities, which 
suggests that for many research organizations, a small number of physicians may be responsible 
for enrolling minorities in treatment trials. Moreover, substantially increasing the size of a 
CCOPs or MBCCOPs may not be feasible due to funding restrictions; therefore, it may be 
important to consider dedicating specific staff members as patient navigators or peer supporters 
who are responsible for helping patients overcome burdens to trial participation. Unfortunately, 
data was unavailable on the existence of patient navigators at CCOPs and MBCCOPs, and it may 
be that either large, or dedicated, research staff is necessary to enhance minority enrollment. 
Further research is necessary to elucidate the impact of specific roles research support staff play 
in making patients aware of clinical trials, giving them the opportunity to participate in trials, and 
gaining their acceptance when offered participation in a treatment trial. 
 Results from Aim 2 also have implications for policy, practice, and research. First, results 
demonstrate that there are multiple logical organizational strategies that result in high enrollment 
of minorities in treatment trials, and those strategies are comprised of varied organizational 
design features. Indeed, a key finding for practice and policy from the fuzzy-set qualitative 
comparative analysis is that a number of CCOP strategies may consistently result in high 
enrollment of minorities in treatment trials. Not surprisingly, the “size matters” strategies have 
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substantial resources at their disposal in the conduct of clinical research. However, a large 
physician cadre may not be sufficient to enroll minorities in trials, whereas supportive policies 
and practices may be necessary in order for CCOPs to reach their full potential with regards to 
enrollment of minorities. Policymakers at the NCI that determine funding for CCOPs and 
MBCCOPs may need to consider the ramifications of locating and funding research 
organizations with substantial research support. Conversely, the results from the fuzzy-set 
analysis demonstrate that MBCCOPs may not need as much in the way of resources – except for 
possibly a large trial menu or supportive policies and practices in order to enroll minorities in 
clinical treatment trials. 
 With regards to research implications, Aim 2 has demonstrated that a fuzzy-set 
qualitative comparative analysis examining 7 organizational tactics with longitudinal data is a 
feasible approach to investigating complex causality with organizational-level data. This appears 
to be the case despite a small, or moderate number of observations - in this case, approximately 
60 observations each year for three years. Preliminary analyses for Aim 2 included six 
organizational design features, and four organizational context features; however, none of the 
strategies in the preliminary analysis met the threshold for consistency (0.80). Future research 
should continue employing fuzzy-set qualitative comparative analysis, or other set-theoretic 
methods, in order to evaluate additional organizational strategies with novel organizational 
context features. Furthermore, after strategies have been logically minimized via Boolean 
Algebra (e.g. Quine-McCluskey algorithm) and evaluated with set-theoretic parameters-of-fit 
(e.g. inclusiveness, consistency, and coverage), case study methods can be employed in order to 
re-examine empirical cases for additional policy and practical needs.  
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 Finally, Aim 3 also has policy, practice, and research implications. The key finding from 
Aim 3 is the demonstrated overall lack of disparities in geographic access to clinical trials 
organizations. The finding that the regions with the most concentrated disparities in geographic 
access to clinical trial organizations are the US Southwest, Mississippi Delta, and Black Belt is 
not particularly surprising. These regions have large rural areas, and high concentrations of 
minority populations. Additionally, spatial analysis of the maps of ZIP code tabulation areas and 
travel times to clinical trial organizations by race reveals that the most widespread disparities in 
geographic access to clinical trials organizations are for white and Hispanic populations. The 
policy implications of these findings are straightforward. In order to reduce or eliminate 
disparities in geographic access to clinical trial organizations, a targeted approach may be 
preferred over a blanket call from NCI for proposals for implementing clinical trial organizations 
in regions where minorities reside. In addition to the targeted approach, additional geospatial 
research can focus on identifying the regions where white and Hispanic populations reside with 
long travel times. In lieu of creating a new clinical trial organization, that information may be 
used by existing clinical trial organizations to seek partner physicians and organizations to 
address the disparities. 
Future Directions 
 
Our results indicate that funding CTOs serving large minority populations can be an 
effective approach to enhancing the participation of minorities in clinical research.  
However, over half of the MBCCOPs in our sample failed to meet overall enrollment targets. 
Findings demonstrate that CTOs that do not serve large minority populations can also enhance 
minority participation in clinical trials. NCORP may wish to consider an approach of 
implementing CTOs located in regions with moderate or large minority populations, with 
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particular attention to hiring research staff dedicated to enhancing minority participation, and 
opening treatment trials appropriate for minority populations. Indeed, only five MBCCOPs 
attained the anchor point of 20 minorities enrolled to treatment trials proposed by officials at the 
NCI Division of Cancer Prevention, whereas nine CCOPs enrolled 20 twenty or more minorities 
to treatment trials from 2010-2012. CTOs may implement training or outreach events, recognize 
the efforts of physicians to enroll patients, and increase their number of research staff in order to 
enhance minority enrollment in treatment trials, regardless of whether it serves a large minority 
population. For example, the Delaware/Christiana CCOP in Newark, Delaware, implements 
monthly training events, provides recognition for enrolling physicians, and has a large research 
staff consistently enrolling more than 20 minority patients to trials annually. Notably, the 
Delaware/Christiana CCOP provides multiple forms of recognition for physician enrollment, 
including: authorship on publications, plaques, and gift certificates, which is a substantial 
amount of recognition compared with other CCOPs. Other organizational strategies employed by 
CTOs may also be effective in enhancing minority participation in trials, and future research is 
necessary to understand additional strategies that can be implemented to improve minority 
participation in treatment trials. 
The research contained in this dissertation provides the backdrop for further studies in 
organizational determinants of minority participation in clinical trials. First, results from Aims 1 
and 2 of this dissertation lay the groundwork for further empirical investigations of 
organizational strategies resulting in enhanced participation of minorities in clinical treatment 
trials. Additional organizational design features can be drawn from the 2011 CCOP 
Administrators Survey, and novel geographic measures will be developed from further spatial 
analysis of each CCOP or MBCCOP and employed in future fuzzy-set qualitative comparative 
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analyses. Second, results from Aim 3 suggest that there are few regions in the continental US 
with disparities in geographic access to clinical trial organizations. Future spatial analyses will 
focus on disparities in geographic access to clinical trials organizations in smaller, detailed 
regions – such as the Deep South or the Southwestern portion of the US. Finally, the geographic 
information system developed in this dissertation provides a foundation for further studies on 
disparities in geographic access to high-quality cancer care in the continental US. In order to 
accomplish this, a refined approach to evaluating which cancer care organizations in the US offer 
high-quality cancer care services must be harnessed. The American Society of Clinical Oncology 
developed the Quality Oncology Practice Initiative to assess the quality of oncology practices in 
the US, which may be adapted to evaluate geographic disparities in access to high-quality cancer 
care organizations. 
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Table 18. Chapter 2: Bivariate Relationships Between Variables 
 
 
 
 
 
 
(1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) 
(1) Black enrollment 1.00 
                  
(2) No. Training events 0.14 1.00 
                 
(3) No. Enrolling sites 0.21 0.08 1.00 
                
(4) No. Enrolling physicians 0.49 0.14 0.52 1.00 
               
(5) Enrollment expectation 0.21 0.13 0.15 0.19 1.00 
              
(6) Enrollment recognition 0.00 0.04 0.17 0.14 0.05 1.00 
             
(7) No. Trials available 0.23 0.23 0.53 0.46 0.28 0.44 1.00 
            
(8) MBCCOP 0.12 
-
0.06 
-
0.31 
-
0.32 
-
0.10 
-
0.43 
-
0.47 1.00 
           
(9) No. Research staff 0.58 0.23 0.48 0.69 0.29 0.27 0.64 
-
0.22 1.00 
          
(10) MSA Black population 0.25 0.05 
-
0.24 
-
0.06 0.00 
-
0.32 
-
0.38 0.37 
-
0.21 1.00 
         
(11) MSA Black HS graduates 
-
0.01 0.04 0.10 0.26 
-
0.05 
-
0.08 
-
0.07 0.05 
-
0.01 0.02 1.00 
        
(12) MSA Black uninsured 
-
0.01 
-
0.06 0.13 0.05 0.15 
-
0.06 0.06 
-
0.19 0.00 
-
0.17 
-
0.11 1.00 
       
(13) MSA Black unemployed 
-
0.07 0.25 0.13 0.07 
-
0.17 0.01 0.19 
-
0.32 0.11 
-
0.08 
-
0.18 0.10 1.00 
      
(14) MSA Black family income 0.12 
-
0.04 
-
0.12 0.06 0.01 
-
0.12 
-
0.25 0.41 
-
0.13 0.48 0.50 
-
0.11 
-
0.57 1.00 
     
(15) Hospital competition 0.34 0.10 
-
0.11 
-
0.04 0.12 
-
0.11 
-
0.14 0.20 
-
0.02 0.74 0.02 
-
0.23 
-
0.03 0.32 1.00 
    
(16) State HMO penetration 
-
0.08 0.00 
-
0.16 
-
0.05 
-
0.01 
-
0.06 
-
0.16 0.10 
-
0.17 0.33 0.01 
-
0.58 
-
0.06 0.31 0.27 1.00 
   
(17) Insurance mandate 0.13 0.15 0.05 0.23 0.07 
-
0.07 0.20 
-
0.02 0.17 
-
0.35 
-
0.08 0.06 0.11 
-
0.18 
-
0.34 0.04 1.00 
  (18) MSA Black population X 
MBCCOP 0.11 0.00 
-
0.25 
-
0.26 
-
0.21 
-
0.31 
-
0.38 0.62 
-
0.18 0.76 
-
0.01 
-
0.20 
-
0.12 0.37 0.59 0.23 
-
0.35 1.00 
 (19) MSA Black education X MSA 
Black unemployment 
-
0.06 0.26 0.15 0.13 
-
0.19 
-
0.01 0.17 
-
0.32 0.11 
-
0.06 0.04 0.07 0.97 
-
0.46 
-
0.01 
-
0.06 0.09 
-
0.12 1.00 
8
5
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Table 19. Regression Results: Impact of Environmental 
Factors on Enrollment of Blacks in Cancer Clinical Treatment 
Trials 
   (MODEL WITHOUT ORG FACTORS) 
 
    
Variable 
Marginal 
Effects 
Standard 
Error♯ P-value 
95% Confidence 
Interval 
MSA Black Population (1000s) 0.001 0.001 0.603 -0.002 0.003 
MSA Proportion Black High School 
Graduates 26.056 21.871 0.234 -16.811 68.923 
MSA Proportion Black Uninsured -7.025 28.699 0.807 -63.273 49.224 
MSA Proportion Black Unemployed 41.137 25.921 0.113 -9.668 91.942 
Hospital Competition 0.206*** 0.039 0.000 0.130 0.282 
State Managed Care Penetration -4.785 11.391 0.674 -27.111 17.540 
State Insurance Coverage Mandate 5.709*** 1.297 0.000 3.167 8.251 
Northeast -0.583 2.344 0.803 -5.178 4.011 
South 8.965*** 2.523 0.000 4.019 13.910 
West -2.964* 1.611 0.066 -6.121 0.193 
Midwest - - - - - 
2010 - - - - - 
2011 -1.022 1.023 0.318 -3.028 0.983 
2012 -1.233 1.129 0.275 -3.447 0.980 
n = 172 
     Pseudo R2 = 0.0895; BIC = 1094.49 
     * p < 0.10; ** p < 0.05; *** p < 0.01 
      Bootstrapped Standard Errors (2000 
replications) 
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